Cost of Illness Study of Anxiety Disorders for the Ambulatory Adult Population of the United States by Shirneshan, Elaheh
University of Tennessee Health Science Center
UTHSC Digital Commons
Theses and Dissertations (ETD) College of Graduate Health Sciences
12-2013
Cost of Illness Study of Anxiety Disorders for the
Ambulatory Adult Population of the United States
Elaheh Shirneshan
University of Tennessee Health Science Center
Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Health and Medical Administration Commons
This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been
accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please
contact jwelch30@uthsc.edu.
Recommended Citation
Shirneshan, Elaheh , "Cost of Illness Study of Anxiety Disorders for the Ambulatory Adult Population of the United States" (2013).
Theses and Dissertations (ETD). Paper 370. http://dx.doi.org/10.21007/etd.cghs.2013.0289.
Cost of Illness Study of Anxiety Disorders for the Ambulatory Adult
Population of the United States
Document Type
Dissertation
Degree Name
Doctor of Philosophy (PhD)
Program
Health Outcomes and Policy Research
Research Advisor
David K. Solomon, Pharm.D.
Committee
James E. Bailey, M.D. Lawrence M. Brown, Pharm.D. Ph.D. Brandi E. Franklin, Ph.D. George Relyea, M.S.
DOI
10.21007/etd.cghs.2013.0289
Comments
One year embargo expired in December 2014
This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/370
  
 
Cost of Illness Study of Anxiety Disorders for the Ambulatory Adult Population of 
the United States 
 
 
 
 
  
 
 
 
A Dissertation 
Presented for 
The Graduate Studies Council 
The University of Tennessee 
Health Science Center 
 
 
 
 
 
 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy 
From The University of Tennessee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
By 
Elaheh Shirneshan 
December 2013 
 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Copyright © 2013 by Elaheh Shirneshan.  
All rights reserved. 
 
 
 iii 
DEDICATION 
 
 
 This dissertation is dedicated to my wonderful parents, Fatemeh and Masoud, to 
whom I owe every bit of my existence, to my beloved husband Ali, who has always 
believed in me and pushed me to do my best, and to my siblings, Emad and Afrooz, for 
their unconditional love and support. 
 
 
 
 
 
  
 iv 
ACKNOWLEDGEMENTS 
 
 
 First, I would like to thank Dr. Lawrence M. Brown, and Dr. David K. Solomon, 
my research advisors, for all of their support and guidance. In addition, I would also like 
to thank my other committee members, Mr. Georg Relyea, Dr. Brandi E. Franklin, and 
Dr. Jim Bailey. Without their diligence and dedication, this dissertation would not have 
been possible.  
 
 
 
  
 v 
ABSTRACT 
 
 
 Background: Anxiety disorders are the most common psychiatric illness in the 
United States. However, economic burdens of this category of mental illnesses have not 
been well studied yet. The objective of this study was to estimate the societal cost of 
anxiety disorders for the ambulatory adult population of the U.S.  
 
 Data and Method: Data was collected from the 2009 and 2010 Medical 
Expenditure Panel Survey (MEPS), Bureau of Labor Statistics (BLS), and National Vital 
Statistics System (NVSS). Cost components included in the analyses were direct medical 
costs (i.e. cost for inpatient visits, outpatient visits, emergency room visits, office-based 
visits, prescription medications, and other services), and indirect cost (i.e. morbidity and 
mortality costs). Anxiety patients were identified using MEPS data. More specifically, 
individuals 18 years and older, who reported a diagnosis of, or had a medical event 
associated with anxiety disorder(s), were classified as anxiety population. Number of 
suicides due to anxiety disorders was estimated using the NVSS data. Direct medical 
costs attributable to anxiety disorders were estimated as the expenditures incurred by 
anxiety patients in excess of those incurred by anxiety-free population. Several 
multivariate regression analyses, using generalized linear models, were conducted to 
calculate the overall incremental direct medical costs associated with anxiety disorders, 
as well as cost by healthcare delivery setting, and cost for different sub-populations. 
Indirect costs were estimated using the Human Capital Approach (HCA). Morbidity cost 
was estimated by valuing the time period in which individuals had to stay in bed due to 
anxiety disorders. Mortality cost was estimated as the productivity loss from age at death 
to life expectancy. 
 
 Results: Among adult participants in 2009-2010 MEPS, 30.35 million (8.74%) 
reported being diagnosed with anxiety disorder(s). It was also estimated that in 2010, 
3,497 suicides were due to anxiety disorders. The annual overall direct medical costs 
associated with anxiety disorders was estimated at $1657.52 per person (SE: $238.83; p 
<0.001), or $33.71 billion in total. Inpatient visits, prescription medications, and office-
based visits together accounted for almost 93% of the overall cost. The increase in direct 
medical cost due to anxiety disorders was higher among White non-Hispanics ($1879.31) 
than Black non-Hispanics ($1459.30). For non-Hispanics, anxiety was not associated 
with a statistically significant increase in medical expenditure. Regarding aspects of 
indirect cost, morbidity and mortality cost were estimated at $12.72 billion and $2.34 
billion in 2013 US dollars, respectively. The 2013 societal cost of anxiety disorders was 
estimated at $48.72 billion. 
 
 Conclusion: The current study demonstrates conclusively that anxiety disorders, 
with the annual cost of $48.72 billion in 2013 US dollars, absorb a significant portion of 
US healthcare resources and should be prioritized by policymakers and healthcare 
providers who aim to reduce downstream costs of mental disorders. 
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CHAPTER 1.    INTRODUCTION 
 
 
 Data on the economic burden of anxiety disorders are limited. But this category of 
mental illnesses is known to be the most prevalent, and one of the most expensive 
psychiatric disorders in the U.S. The current study intends to answer the following 
research question: What are the economic burdens of anxiety disorders to the ambulatory 
adult population of the U.S.? 
 
 The following sections describe the importance of conducting a cost of illness 
study for anxiety disorders, the existing gap in the relevant literature, the potential 
contributions of this research to the current literature, and detailed explanation of specific 
aims of the study.  
 
 
Importance of Conducting a Cost of Illness Study for Anxiety Disorders 
 
 
Why a Cost of Illness Analysis? 
 
 According to Centers for Medicare & Medicaid Services (CMS) “U.S. health care 
spending reached $2.7 trillion in 2011, or $8,680 per person.”1(p. 2) There has been a 
growing rate of 3.9 percent in health spending since 2009. Also from 2009 to 2011, 
health spending was 17.9 percent of Gross Domestic Product (GDP). In comparison with 
other countries in the Organization for Economic Cooperation and Development 
(OECD), the United States has the highest health spending in terms of share of GDP. In 
fact, “Americans spent more than twice as much as relatively rich European countries 
such as France, Sweden and the United Kingdom.”2(p. 1) CMS has projected for this share 
to rise to 20 percent of GDP by 2020. 
 
 There is no simple and straightforward solution for controlling this high and ever-
increasing rate of spending on healthcare in the United States; but, identifying the most 
expensive medical conditions and trying to alleviate their economic burden, through 
disease management interventions, is definitely a required step to be undertaken in this 
way. According to Joel & Segel, “Cost-of-illness studies measure the economic burden of 
a disease or diseases and estimate the maximum amount that could potentially be saved 
or gained if a disease were to be eradicated.”3(p. 2) In developing cost-containment policies 
and interventions, cost of illness (COI) analysis enables policymakers to identify diseases 
which need to be addressed with the highest priority. 
 
 No one can argue that healthcare resources, like many other forms of resource, are 
scarce; and the more resources absorbed by heath sector, the less will be left for other 
sectors such as education, defense, etc. A cost of illness study is not enough to set 
priorities for the objective of resource allocation (for that purpose, one needs 
effectiveness data as well as cost data). However, it is a main component of any cost-
effectiveness or cost-utility analysis. Nowadays, cost of illness studies are being widely 
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used by health economists, pharmaceutical companies, clinicians, and policymakers to set 
research agendas and allocate resources.4,5 
 
 
Why Examining Costs by Service Category and for Different Sub-populations? 
 
 Even though cost of illness analysis is a crucial primary step in identifying costly 
medical conditions, further information is needed if effectively reducing the burden of 
these conditions is desired. To reduce the burden of illness, just knowing the dollar 
amount in terms of cost of illness is not enough. In fact, one also needs to know the 
distribution of costs among different health sectors (inpatient, outpatient, emergency 
room, prescription medication …) and subpopulations (based on gender, race, age …) to 
find out if resources are being distributed disproportionally. Knowing which 
subpopulations or health sectors incur higher costs, policymakers can come up with 
tailored disease management interventions to address high costs specifically in those sub-
populations/health sectors.  
 
 Healthcare costs are not distributed proportionally among different sub-
populations. According to the Medical Expenditure Panel Survey (MEPS), in 2010, 
individuals with some college degree had the highest total healthcare expenditure in 
comparison with those in other educational levels. The same can be said for Whites, 
females, and married individuals. So having the estimation of cost of illness for the whole 
population (who suffer from that disease), one also needs to know how this burden is 
distributed among different groups of people. In the same manner, distribution of cost 
among different service categories will yield useful information as to which category of 
health services may benefit the most from disease management programs. 
 
 
Why Anxiety Disorders? 
 
 Costly medical conditions can be amongst the underlying causes of skyrocketing 
healthcare expenditures in the U.S. In this regard, it is good to know that one group of 
these expensive medical conditions are anxiety disorders. Anxiety is a natural response 
and a necessary warning adaptation in humans. Everybody has experienced anxiety in the 
form of increased heart rate and tensed muscles. However, anxiety can become a 
pathologic disorder when it is excessive and uncontrollable; In other words, when it 
occurs without any recognizable reason or when the reason does not warrant such a 
reaction. If no medical condition accounts for symptoms, they are attributed to anxiety 
disorders.6 
 
 According to the Diagnostic and Statistical Manual of Mental Disorders, fourth 
edition, text revision (DSM IV-TR),7 anxiety disorders categorize a large number of 
disorders including acute stress disorder, post-traumatic stress disorder (PTSD), phobias 
(including social phobia), agoraphobia (with or without a history of panic disorder), panic 
disorder (with or without agoraphobia), generalized anxiety disorder (GAD), obsessive-
compulsive disorder (OCD), and anxiety disorders due to known physical causes (these 
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include general medical conditions or substance abuse). The primary feature of these 
disorders is abnormal or inappropriate anxiety. These disorders usually interfere with a 
patient’s work, schooling, and family life so that in severe cases, they can adversely 
affect their function. For instance, anxiety disorders can be an underlying cause of 
alcohol and substance abuse.  
 
 Fortunately, anxiety disorders are highly treatable, and most people with these 
conditions can have fulfilling lives if they receive appropriate treatment. In general, 
anxiety disorders are treated with medication, specific types of psychotherapy, or both. 
“Treatment choices depend on the problem and the person’s preference. Before treatment 
begins, a doctor must conduct a careful diagnostic evaluation to determine whether a 
person’s symptoms are caused by an anxiety disorder or a physical problem.”8(p. 14) 
 
 Each year, almost one out of three Americans age 18 years or older (12-month 
prevalence=26.2%), will experience at least one form of mental disorders (i.e. anxiety 
disorders, mood disorders, impulse-control disorders, and substance use disorders).9 More 
than two thirds of these individuals (12-month prevalence=18.1%) suffer from one (or 
more) form of anxiety disorders (alone or along with another mental condition).9 In other 
words, anxiety disorders represent the most common psychiatric illnesses in the U.S. The 
annual societal cost of anxiety disorders in the U.S. in 1990 was estimated to range from 
US$42 to US$47 billion, nearly approaching the estimates of the cost of depression (from 
US$44 to US$53 billion) for the same time frame.5,10 With respect to the high prevalence 
of anxiety disorders in the U.S. and evidence from previous research,5,10 it is expected 
that this category of mental illnesses imposes a significant economic burden to society. In 
this regard, a more current and comprehensive evaluation of healthcare expenditures 
attributable to anxiety disorders is warranted. Such evaluation may guide clinicians and 
policymakers in developing and improving disease management programs, and provide a 
basis for conducting cost-effectiveness analysis of new treatment interventions. 
 
 
The Existing Gap in the Literature 
 
 In order to have a reliable estimation of the economic burden of a disease to 
society, there are several factors that must be taken into account: 
 
? Both direct and indirect costs should be included in the analysis. 
 
? The sample should be representative of the entire population in which results are 
to be generalized to. 
 
? If there is more than one diagnosis for a condition, all possible diagnoses should 
be considered. 
 
? In estimating the costs, not only the costs directly due to the condition of interest 
should be included, but also costs due to the comorbidities and complications 
resulted from that condition should be considered. 
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? When using different data sources, the potential inconsistency between these data 
sources should be taken into account. 
 
 An overview of the literature on cost of illness studies for anxiety disorders 
reveals that there are a limited number of studies in this field. In fact, the only studies that 
estimated direct and indirect costs of anxiety disorders from a societal perspective in the 
U.S. were conducted far back, in 1996 and 1999 by DuPont et al.5 and Greenberg et al.10 
 
 DuPont et al.5 conducted a cost of illness analysis from a societal perspective, by 
including direct medical costs, direct non-medical costs, and indirect costs (morbidity and 
mortality costs). The major limitation of their study is that in estimating the cost of illness 
for anxiety disorders, they only considered the costs that were incurred directly due to 
anxiety disorders; but they did not account for the increase in general use of medical 
services in patients suffering from anxiety disorders. In addition, they did not include all 
diagnoses of anxiety disorders in their analysis (data on costs due to PTSD and acute 
stress disorder were not collected). All of this might have led to an underestimation of the 
true burden of anxiety disorders. Another limitation of the study is related to the data 
collection process. Data on utilization and cost was collected from several different data 
sources. For instance, they used more than six databases (such as National Hospital 
Discharge Survey, National Nursing Home Survey, Pharmaceutical Data Source …) for 
calculating direct medical costs. The potential inconsistencies between different data 
sources may later cast doubt on the reliability of results.  
 
 Greenberg et al.10 reduced the inconsistency in data by using less data sources. 
They collected the majority of data from the National Comorbidity Survey. The cost 
components included in their study were direct psychiatric costs, direct non-psychiatric 
costs, and indirect costs (morbidity and mortality costs). Direct non-psychiatric costs 
accounted for most of the cost of illness for anxiety disorders. However, estimation of 
this cost component (which accounted for more than half of their estimated cost of 
illness) was based on results from a single staff–model HMO that may not be fully 
generalizable to the entire population. So, their estimation of cost of illness for anxiety 
disorders may not be representative of the true burden of this condition to the whole 
society. In addition, they did not include all diagnoses of anxiety disorders in their 
analysis (data on costs due to OCD and acute stress disorder were not collected).  
 
 In more recent studies, the study population is either not from the U.S. or not 
representative of the whole U.S. population,11-15 the perspective is not societal,11,16-22 both 
direct and indirect costs are not estimated,11,15-23 or not all anxiety diagnoses are included 
in the study.16,17,24-29 
 
 
Potential Contributions of This Research to the Current Literature 
 
 Due to the high prevalence of anxiety disorders in the U.S. and the evidence from 
previous research on anxiety-related costs,5,10 it is expected that this category of mental 
illnesses imposes a significant economic burden to society. Considering the fact that 
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costly medical conditions have been always a high priority to policymakers in their effort 
to reduce healthcare costs, a well-conducted cost of illness for anxiety disorders can 
provide them with a reliable estimation of the economic burden of these conditions. 
Moreover, identifying the distribution of costs among different sub-populations and 
health sectors may enable them to come up with tailored disease management programs 
to reduce the costs.  
 
 The specific features of the study which distinguish it from the previous works, 
and also add to the current knowledge are as follows: 
 
? Results of this research will provide the most comprehensive and updated 
estimate of cost of illness for anxiety disorders, for the ambulatory adult 
population of the U.S. 
 
? It is the first study that measures costs at the population level, as well as for 
different sub-populations. 
 
? The sample is representative of the whole U.S civilian non-institutionalized 
population 18 years of age and older. So, results can be generalized to this group 
of individuals (Civilian-non-institutionalized population refers to community-
dwelling population or ambulatory population. individuals in the military and 
those residing in nursing homes, assisted living facilities, and prisons are not 
included in the civilian-non-institutionalized population. Throughout this 
research, civilian non-institutionalized population and ambulatory population 
phrases are used alternatively). 
 
? The societal perspective enables the researcher to measure the economic burdens 
of anxiety disorders to the whole society regardless of who incurred the costs. 
 
? Instead of getting data from several different data sources, which may lead to 
inconsistency in data and later affect the reliability of results, only one database 
will be used to collect data on healthcare utilization and costs.  
 
? All possible diagnoses of anxiety disorders will be included in the analysis. 
 
? The estimation of cost of illness will not only capture the costs directly due to 
anxiety disorders, but it will also include cost of their comorbidities and 
complications.  
 
? The analysis technique used will control for all factors that may affect healthcare 
expenditures, therefore, researchers can estimate costs solely due to anxiety 
disorders. 
 
 
 
 6 
Specific Aims 
 
 Specific aims of the study are presented in this section. For all specific aims, 
estimates will be provided for the ambulatory adult (18 years and older) population of the 
U.S.  
 
? Specific Aim 1 (SA1): To estimate direct medical cost and indirect costs 
(morbidity cost, mortality cost) of anxiety disorders. 
 
? Specific Aim 2 (SA2): To estimate direct medical costs attributable to anxiety 
disorders by major service categories (i.e. inpatient visits, outpatient visits, office-
based medical visits, emergency room visits, prescription medications, and other 
services). 
 
? Specific Aim 3 (SA3): To estimate direct medical costs attributable to anxiety 
disorders for different sub-populations (based on gender, race/ethnicity, age, 
marital status, poverty category, education, geographic region, Metropolitan 
Statistical Area (MSA), and insurance coverage). 
  
 7 
CHAPTER 2.    LITERATURE REVIEW 
 
 
 The goal of this chapter is to provide a review of literature relevant to the purpose 
of this research. It has two main sections. The first section provides an introduction to 
anxiety disorders, their epidemiology and treatments. The second section is devoted to 
cost of illness studies. It starts with description and history of cost of illness studies and 
continues with reviewing the cost of illness studies for anxiety disorders. In order to find 
these studies, we conducted a search in Pubmed, Ovid, PsycINFO, and Google Scholar 
for articles published after 1990. The search words were cost, expenditure, cost of illness, 
burden, and anxiety disorders.  
 
 
An Overview of Anxiety Disorders 
 
 
Description of Anxiety Disorders 
 
 According to the American Psychiatric Association,7 anxiety disorders categorize 
a large number of disorders including acute stress disorder, agoraphobia (with or without 
a history of panic disorder), generalized anxiety disorder (GAD), obsessive-compulsive 
disorder (OCD), panic disorder (with or without Agoraphobia), phobias (including social 
phobia), and post-traumatic stress disorder (PTSD). The primary feature of these 
disorders is abnormal or inappropriate anxiety. Everybody has experienced anxiety in 
forms of increased heart rate and tensed muscles. But anxiety becomes a problem when it 
occurs without any recognizable reason, or when the reason does not warrant such a 
reaction. If no medical condition accounts for symptoms, they are attributed to anxiety 
disorders.6 
 
 The following sections provide information on etiology, symptoms and prognosis 
of different diagnoses of anxiety disorders, quoted from AllPsych Online 
(http://allpsych.com/disorders/anxiety/index.html).6 
 
 
Acute Stress Disorder 
 
? Etiology: “By definition, acute stress disorder is a result of a traumatic event in 
which the person experienced or witnessed an event that involved threatened or 
actual serious injury or death and responded with intense fear and helplessness.”6 
 
? Symptoms: “Symptoms include dissociative symptoms such as numbing, 
detachment, a reduction in awareness of the surroundings, derealization, or 
depersonalization; re-experiencing of the trauma, avoidance of associated stimuli, 
and significant anxiety, including irritability, poor concentration, difficulty 
sleeping, and restlessness. The symptoms must be present for a minimum of two 
days and a maximum of four weeks and must occur within four weeks of the 
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traumatic event for a diagnosis to be made.”6 
 
? Prognosis: “Prognosis for this disorder is very good. If it should progress into 
another disorder, success rates can vary according to the specific of that 
disorder.”6 
 
 
Agoraphobia (with or without a History of Panic Disorder) 
 
? Etiology: “Agoraphobia can develop out of simple phobias or it can be a result of 
extreme trauma, although it is often a result of numerous panic attacks such as 
those found in panic disorder.”6 
 
? Symptoms: “Agoraphobia, like other phobias, is made up of extreme anxiety and 
fear. Different from other phobias, however, is the generalization which occurs. 
Agoraphobia is the anxiety about being in places where escape might be difficult 
or embarrassing or in which help may not be available should a panic attack 
develop. It can be sub diagnosed as either ‘with’ or ‘without’ panic disorder. 
Typically situations that invoke anxiety are avoided and in extreme cases, the 
person may never or rarely leave their home.”6 
 
? Prognosis: “Prognosis is good, especially if the individual has some insight into 
the development of the disorder and if their fears are irrational and there is insight 
into this.”6 
 
 
Generalized Anxiety Disorder (GAD) 
 
? Etiology: “Often anxiety gets generalized to other situations, and can then become 
overwhelming or associated with life in general. Typically GAD develops over a 
period of time and may not be noticed until it is significant enough to cause 
problems with functioning.”6 
 
? Symptoms: “As its name implies, GAD is evidenced by general feelings of 
anxiety such as mild heart palpitations, dizziness, and excessive worry. The 
symptoms are difficult to control for the individual and are not related to a 
specific event (such as in PTSD) and are not as severe as those found with Panic 
Disorder.”6 
 
? Prognosis: “Prognosis is good for the more extreme symptoms, but those 
associated with underlying fears are more difficult to treat (such as excessive 
worry). Working through childhood issues can be helpful as these tend to get 
distorted as they follow us into adulthood (e.g., over-controlling parental styles, 
sexual abuse, and childhood phobias).”6 
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Obsessive-compulsive Disorder (OCD) 
 
? Etiology: “Both biological and psychological causes have been found in OCD.”6 
 
? Symptoms: “The key features of this disorder include obsessions (persistent, often 
irrational, and seemingly uncontrollable thoughts) and compulsions (actions 
which are used to neutralize the obsessions). A good example of this would be an 
individual who has thoughts that he is dirty, infected, or otherwise unclean which 
are persistent and uncontrollable. In order to feel better, he washes his hands 
numerous times throughout the day, gaining temporary relief from the thoughts 
each time. For these behaviors to constitute OCD, it must be disruptive to 
everyday functioning (such as compulsive checking before leaving the house 
making you extremely late for all or most appointments, washing to the point of 
excessive irritation of your skin, or inability to perform everyday functions like 
work or school because of the obsessions or compulsions).”6 
 
? Prognosis: “Prognosis for this disorder has a wide range, depending upon how the 
individual responds to medication and how deep rooted the underlying issues 
are.”6 
 
 
Panic Disorder (with or without Agoraphobia) 
 
? Etiology: “Often the symptoms of this disorder come on rapidly and without an 
identifiable stressor. The individual may have had periods of high anxiety in the 
past, or may have been involved in a recent stressful situation. The underlying 
causes, however, are typically subtle.”6 
 
? Symptoms: “Panic Disorder is characterized by sudden attacks of intense fear or 
anxiety, usually associated with numerous physical symptoms such as heart 
palpitations, rapid breathing or shortness of breath, blurred vision, dizziness, and 
racing thoughts. Often these symptoms are thought to be a heart attack by the 
individual, and many cases are diagnosed in hospital emergency rooms.”6 
 
? Prognosis: “Prognosis for this disorder is very good if the above conditions are 
met. Left untreated, however, symptoms can worsen and Agoraphobia can 
develop. In these cases, the individual has developed such an intense fear that 
leaving the safety of home feels impossible.”6 
 
 
Phobias (Including Social Phobia) 
 
? Etiology: “Often a traumatic event is the precursor for a phobia, which may or 
may not be at the conscious level.”6 
 
? Symptoms: “Symptoms include either extreme anxiety and fear associated with 
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the object or situation or avoidance. To be diagnosed, the symptoms must be 
disruptive to everyday functioning (such as quitting a great job merely because 
you have to use an elevator).”6 
 
? Prognosis: “Prognosis is very good if treated effectively.”6 
 
 
Post-traumatic Stress Disorder (PTSD) 
 
? Etiology: “By definition, PTSD always follows a traumatic event which causes 
intense fear and/or helplessness in an individual. Typically the symptoms develop 
shortly after the event, but may take years. The duration for symptoms is at least 
one month for this diagnosis.”6 
 
? Symptoms: “Symptoms include re-experiencing the trauma through nightmares, 
obsessive thoughts, and flashbacks (feeling as if you are actually in the traumatic 
situation again). There is an avoidance component as well, where the individual 
avoids situations, people, and/or objects which remind him or her about the 
traumatic event (e.g., a person experiencing PTSD after a serious car accident 
might avoid driving or being a passenger in a car). Finally, there is increased 
anxiety in general, possibly with a heightened startle response (e.g., very jumpy, 
startle easy by noises).”6 
 
? Prognosis: “Prognosis ranges from moderate to very good. Those with the best 
prognosis include situations where the traumatic event was acute or occurred only 
one time (e.g., car accident) rather than chronic or on-going trauma (e.g., ongoing 
sexual abuse, war).”6 
 
 
Epidemiology of Anxiety Disorders 
 
 For any anxiety disorder, 12-month prevalence is 18.1% of the U.S. adult 
population.9 Lifetime prevalence is 28.8% of the U.S. adult population and 25.1% of 
children and adolescents.30 Women are 60% more likely than men to experience an 
anxiety disorder over their lifetime. Non-Hispanic Blacks are 20% less likely, and 
Hispanics are 30% less likely, than non-Hispanic Whites to experience an anxiety 
disorder during their lifetime. Individuals in the age group of 30-44 have the highest risk 
of developing an anxiety disorder over their lifetime (35.1%), while those who are 60 or 
older have the lowest risk (15.3%).30 Table 2-1 shows the epidemiology of anxiety 
disorders in the U.S. adult population for each specific diagnosis. 
 
 
Treatment of Anxiety Disorders 
 
 According to the National Institute of Mental Health (NIMH) “anxiety disorders 
are treated with medication, specific types of psychotherapy, or both. Treatment choices 
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Table 2-1. Prevalence of anxiety disorders for the U.S. adult population. 
 
Diagnosis  Lifetime prevalence  12-month prevalence 
Any Anxiety Disorder  28.8%  18.1% 
Acute Stress Disorder  7.8%  - 
Agoraphobia  1.4%  0.8% 
Generalized Anxiety Disorder  5.7%  3.1% 
Social Phobias  12.1%  6.8% 
Specific Phobias  12.5%  8.7% 
Post-traumatic Stress Disorder   6.8%  3.5% 
Obsessive-compulsive Disorder   1.6%  1.0% 
Panic Disorder  4.7%  2.7% 
 
Source: Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, 
severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity 
Survey Replication. Arch Gen Psychiatry. Jun 2005;62(6):617-627; Kessler RC, 
Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age 
of-onset distributions of DSM-IV disorders in the National Comorbidity Survey 
Replication. Arch Gen Psychiatry. Jun 2005;62(6):593-602. 
 
 
depend on the problem and the person’s preference. Before treatment begins, a doctor 
must conduct a careful diagnostic evaluation to determine whether a person’s symptoms 
are caused by an anxiety disorder or a physical problem.”8(p. 14)  
 
 The following sections, quoted from the Booklet of Anxiety Disorders,8 describe 
treatment options for anxiety disorders. 
 
 
Medication 
 
 “Medication will not cure anxiety disorders, but it can keep them under control 
while the person receives psychotherapy.”8(p. 14) Antidepressants, anti-anxiety drugs, and 
betablockers are the three major categories medications used for anxiety disorders. 
 
 Antidepressants. Even though Antidepressants were originally developed to treat 
depression, they are also effective in treating anxiety disorders.8 The specific 
antidepressant used to treat anxiety disorders are listed below: 
 
? Selective serotonin reuptake inhibitors (SSRIs): “SSRIs alter the levels of the 
neurotransmitter serotonin in the brain, which, like other neurotransmitters, helps 
brain cells communicate with one another. Fluoxetine (Prozac®), sertraline 
(Zoloft®), escitalopram (Lexapro®), paroxetine (Paxil®), and citalopram 
(Celexa®) are some of the SSRIs commonly prescribed for panic disorder, OCD, 
PTSD, and social phobia. SSRIs are also used to treat panic disorder when it 
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occurs in combination with OCD, social phobia, or depression. Venlafaxine 
(Effexor®), a drug closely related to the SSRIs, is used to treat GAD. These 
medications are started at low doses and gradually increased until they have a 
beneficial effect. SSRIs have fewer side effects than older antidepressants. Their 
common side effects are slight nausea or jitters (when people first start to take 
them) as well as sexual dysfunction.”8(p. 15) 
 
? Tricyclics: “Tricyclics are older than SSRIs and work as well as SSRIs for anxiety 
disorders other than OCD. Tricyclics include imipramine (Tofranil®), which is 
prescribed for panic disorder and GAD, and clomipramine (Anafranil®), which is 
the only tricyclic antidepressant useful for treating OCD. They are also started at 
low doses that are gradually increased. They sometimes cause dizziness, 
drowsiness, dry mouth, and weight gain.”8(p. 15) 
 
? MAOIs: “Monoamine oxidase inhibitors (MAOIs) are the oldest class of 
antidepressant medications. The MAOIs most commonly prescribed for anxiety 
disorders are phenelzine (Nardil®), followed by tranylcypromine (Parnate®), and 
isocarboxazid (Marplan®),which are useful in treating panic disorder and social 
phobia. If taken with food and beverages containing tyramine or certain 
medications, including some types of birth control pills, pain relievers, cold and 
allergy medications, and herbal supplements drug interaction will occur which 
leads to increase in blood pressure.”8(p. 16) 
 
 Anti-anxiety drugs. “High potency benzodiazepines combat anxiety and its main 
side effect is that patient may get dependent to it. Clonazepam (Klonopin®) is used for 
social phobia and GAD, lorazepam (Ativan®) is helpful for panic disorder, and 
alprazolam (Xanax®) is useful for both panic disorder and GAD. This drug in now less 
prescribed due to its side effects.”8(p. 16) 
 
 Betablockers. “Betablockers such as propranolol (Inderal®), which is used to 
treat heart conditions, can prevent the physical symptoms that accompany certain anxiety 
disorders, particularly social phobia.”8(p. 17) 
 
 
Psychotherapy 
 
 “Psychotherapy involves talking with a trained mental health professional, such as 
a psychiatrist, psychologist, social worker, or counselor, to discover what caused an 
anxiety disorder and how to deal with its symptoms.”8(p. 17) One of the specific forms of 
psychotherapy, which is very effective in treating some forms of anxiety disorders, is 
called Cognitive Behavioral Therapy (CBT). According to the booklet of NIMH on 
anxiety disorders:  
 
CBT is very useful in treating anxiety disorders. The cognitive part helps people 
change the thinking patterns that support their fears, and the behavioral part helps 
people change the way they react to anxiety-provoking situations. There is some 
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evidence that the benefits of CBT last longer than those of medication for people 
with panic disorder, and the same may be true for OCD, PTSD, and social phobia. 
If a disorder recurs at a later date, the same therapy can be used to treat it 
successfully a second time. Medication can be combined with psychotherapy for 
specific anxiety disorders, and this is the best treatment approach for many 
people.8(p. 17) 
 
 
Diagnosis Specific Treatment 
 
 The following sections, quoted from AllPsych Online 
(http://allpsych.com/disorders/anxiety/index.html),6 provide treatment recommendations 
for each specific diagnosis of anxiety disorder. 
 
? Acute Stress Disorder: “The disorder may resolve itself with time or may develop 
into a more severe disorder such as PTSD.  Medication can be used for a very 
short duration (up to four weeks) or psychotherapy can be utilized to assist the 
victim in dealing with the fear and sense of helplessness.”6 
 
? Agoraphobia: “(with or without a history of panic disorder): Treatment may 
involve anxiety reduction techniques aimed at increasing the control a person 
feels over his or her anxiety and fears. Other approaches require the individual to 
work through their anxiety in relation to interpersonal or childhood issues.”6 
 
? Generalized Anxiety Disorder (GAD): “Medication and/or psychotherapy have 
been found to be helpful, especially therapy aimed at teaching the client how to 
gain control over the symptoms.”6 
 
? Obsessive-compulsive Disorder (OCD): “Medication is often prescribed for 
individuals with OCD. Psychotherapy can be helpful in learning ways to feel 
more in control, cope better with stressors, and explore the underlying issues 
associated with the obsessive thoughts.”6 
 
? Panic Disorder (with or without Agoraphobia): “Although medication can be 
useful, psychotherapy (especially behavioral and cognitive/behavioral approaches 
have proved quite successful). The key to treatment is accepting the panic attacks 
as psychological rather than physical (once these causes have been ruled out by a 
physician), practicing relaxation exercises, and working through the underlying 
issues.”6 
 
? Phobias (including Social Phobia): “Treatment is often behavioral in nature, with 
the therapist guiding the client through exercises more closely resembling the 
feared object or situation. Exploring underlying issues can also be beneficial.”6 
 
? Post-traumatic Stress Disorder (PTSD): “Psychological treatment is considered 
the most effective means to recovery from PTSD, although some medications 
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(such as anti-anxiety meds) can help alleviate some symptoms during the 
treatment process.”6 
 
 
An Overview of Cost of Illness Analysis 
 
 
Description of Cost of Illness Analysis 
 
 According to Joel & Segel, “Cost-of-illness studies measure the economic burden 
of a disease or diseases and estimate the maximum amount that could potentially be 
saved or gained if a disease were to be eradicated.”3(p. 2) Both direct and indirect costs are 
included in a comprehensive analysis. However, based on the perspective of a study, 
either of these cost categories can be excluded.3 
 
 Direct and indirect costs. Direct costs refer to the opportunity cost of resources 
used for treating a particular disease. However in measuring indirect costs, the main 
focus is on the value of resources lost due to a particular disease.31 According to Hodgson 
and Meiners, opportunity cost is defined as “the value of the forgone opportunity to use 
in a different way those resources that are used or lost due to illness.”3(p. 4)  
 
 Direct costs include direct medical costs and nonmedical direct costs. Direct 
medical costs include costs for hospital inpatient stays, emergency room visits, office-
based medical visits, outpatient visits, prescription medication, nursing home care, 
hospice care, rehabilitation care, home health care, and cost for medical supplies.31,32 
Nonmedical direct costs include costs due to transportation to health care facilities; 
relocation and any other change in one’s life pattern due to the illness.3 Indirect costs 
include mortality cost (cost of premature death due to the illness) and morbidity cost 
(productivity loss). 
 
 There are studies in which intangible costs i.e. costs of pain and suffering are 
included in the analysis as well. However, estimation of intangible costs is less common 
due to difficulty in measuring these costs.3 
 
 Perspective. One of the most important aspects of any economic evaluation is the 
perspective of the study. In fact, inclusion and exclusion of the above discussed cost 
categories depend on the perspective undertaken in the study. There are several different 
perspectives that can be used in economic evaluations. For instance, one perspective 
measures the costs to the society (societal perspective) and another one may take into 
account costs to the third party payer (payer perspective). There are other perspectives in 
which costs to businesses, the government, and participants and their families are 
included.4,31 
 
 Incidence-based versus prevalence-based approach. In an incidence-based 
study, the attempt is to estimate the lifetime cost for a patient with a particular illness. 
Here the lifetime cost refers to the cost of an illness from diagnosis to cure or death. On 
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the other hand, in prevalence-based studies, all costs for a particular population in a given 
time period (regardless of the date of onset) will be measured. Requiring less data and 
fewer assumptions than incidence-based studies, prevalence based studies are far more 
common.3 
 
 Measuring indirect costs. There are three primary approaches to estimate 
indirect costs including the Human Capital approach (HCA), the friction cost method, 
and the willingness to pay approach. In the HCA, the lost production for employed 
patients/caregivers is measured in terms of lost earnings.33,34 If the patient/care giver is 
not employed, the value of household work would be equivalent to the cost of hiring a 
replacement from the labor market.3 
 
 Friction cost method is a more realistic approach to measure indirect costs. The 
assumption here is that as long as unemployment rate is greater than zero, the market 
would be able to replace the lost work force. So, the loss of an employee will lead to 
production loss until the new employee is hired and trained.35-37 This period is called the 
friction period. 
 
 Finally, indirect costs can be measured using the willingness to pay approach. 
According to Joel & Segel, “The willingness to pay approach measures the amount an 
individual would pay to reduce the probability of illness or mortality.”3(p. 14)  
 
 Top-down or bottom-up approach. In top-down approach, highly aggregated 
data sources (on population-level) would be directly used. While in bottom-up approach, 
the individual-level data (adopted from patients, patient’s chart, epidemiological 
registries or cohort studies) would be aggregated to get the population-level data.38 
 
 
History of Cost of Illness Studies  
 
 Cost-of-illness studies were among the first economic evaluation studies and first 
appeared in the literature in 1913 in a paper called The value of human life.39 Later in the 
1950s and 1960s, other researchers tried to develop the cost of illness methodology 
further.34,40,41 
 
 In 1959, Mushkin and Collings tried to clarify cost concepts in cost of illness 
studies. They introduced a classification of costs “based on their effects on the use, 
distribution, and quantity of economic resources”.40(p. 795) In 1966, Dorothy Rice 
developed a framework for calculating single-year costs of illness, disability, and death 
by major category of illness, using existing data sets. She also tried to address the 
problems in which a researcher encounters in measuring direct and indirect costs.34 Later, 
this method became a standard approach for conducting a cost of illness study. Since 
1966, Rice has updated and refined her methodology. 
 
 Cost of illness studies became more popular in the 1970s and 1980s, when they 
were used to gain support for more resources being devoted to health care.42 Later in 
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1990s, pharmaceutical companies started to use cost of illness studies to highlight the 
economic burden of a particular disease. The aim was to justify the fact that more 
resources, i.e. the company’s product, should be devoted to that particular disease.42 
Nowadays, cost of illness studies are being widely used by health economists, 
pharmaceutical companies, clinicians, and policymakers to set research agendas and 
allocate resources.4,5 
 
 
Review of Cost of Illness Studies for Anxiety Disorders 
 
 An overview of the literature on cost of illness studies for anxiety disorders 
revealed that there are quite a few studies in this field. In general, these studies form up 
two separate categories. One category includes the studies in which the main purpose was 
to calculate the cost of illness for anxiety disorders. This category by itself has two 
different subcategories: cost of illness studies for multiple diagnoses of anxiety disorders, 
and cost of illness studies for a particular diagnosis of anxiety disorder. Another major 
category consists of studies in which obtaining the cost of illness was not the main 
purpose of the study. For instance, some have calculated the cost as part of a cost-
effectiveness study for a particular treatment of anxiety disorders, while some tried to 
determine the predictors of cost for anxiety disorders. 
 
 
Studies in Which the Main Purpose Was to Calculate COI for Anxiety Disorders 
 
 In this section, studies with the objective of calculating cost of illness for anxiety 
disorders are reviewed. 
 
 COI studies for multiple diagnoses of anxiety disorders. DuPont et al.5 and 
Greenberg et al.10 estimated the direct and indirect costs of anxiety disorders in U.S. in 
1990s. Goetzel et al.11 assessed the health and productivity cost burden of the top ten 
physical and mental health conditions, including anxiety disorders, affecting six large 
U.S. employers; while Marciniak et al.15 tried to estimate the cost of anxiety disorders 
among the employed individuals in the United States. Andlin-Sobocki et al.13 conducted a 
study to estimate the cost of anxiety disorders in Europe and Smit et al.14 estimated the 
costs of nine common mental disorders, including anxiety disorders, in Netherlands.  
 
 COI studies for a particular diagnosis of anxiety disorders. Siegel et al.,24 
Leon et al.,16 and Batelaan et al.28 assessed the costs of panic disorder in the U.S., and 
Netherlands, respectively. While Patel et al.27 and Acarturk et al.29 estimated the 
economic consequences of social phobia in the Great Britain and Netherlands. Rees et 
al.17 compared medical utilization and costs incurred by people with panic disorder to 
those incurred by people with social phobia. 
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Studies in Which Obtaining the COI Was Not the Main Purpose of the Study 
 
 Below is the list of studies falling in this category: 
 
? Salvador-Carulla et al.26 estimated the costs before and after the diagnosis and the 
provision of effective treatment for panic disorder.  
 
? Souetre et al.25 examined how co-morbidity and symptom severity related to the 
costs of generalized anxiety disorder (GAD). 
 
? Marciniak et al.18 examined the different clinical and demographic characteristics 
that could affect the cost of treating patients with anxiety disorders.  
 
? Roberge et al.23 examined healthcare services utilization and costs before and 
after providing an empirically supported cognitive-behavioral treatment for panic 
disorder with agoraphobia. 
 
? McLaughlin et al.20 conducted a study aimed at measuring the impact of having 
both depression and anxiety, having neither or either condition alone on treatment 
patterns, health care utilization, and cost. 
 
? Stein et al.21 tried to find out how antidepressant adherence, among patients with 
anxiety disorders, will affect medical resource use and costs.  
 
? Olfson and Gameroff 22 conducted a study to evaluate the extent to which pain 
severity contributes to the health care costs of patients with generalized anxiety 
disorder (GAD). 
 
 
Specific Features of the COI Studies for Anxiety Disorders 
 
 In the following sections, each of the above-mentioned studies is assessed with 
respect to the main features of a cost of illness analysis. 
 
 Source of data. In order to get data on resource use and cost, almost half of the 
studies used retrospective cohort study methodology. In some of these studies, patients 
were asked retrospectively about their utilization,16,17,24,25,29 while in other studies, 
medical databases providing individual information on healthcare utilization and cost 
were used to obtain required data.5,10,11,13,15,18,20,21 Table 2-2 shows the list of these 
databases.  
 
 Top-down or bottom-up approach. Only two studies used the top-down 
approach to calculate cost of illness for anxiety disorders.5,10 Other studies used the 
bottom-up approach. 
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Table 2-2. Data sources used in COI studies of anxiety disorders. 
 
Authors Data source 
DuPont et al.5 National Institute of Mental Health (NIMH) 
National Hospital Discharge Survey 
American Medical Association 
National Center for Health Statistics 
National Nursing Home Survey 
Pharmaceutical Data Source 
  
Greenberg et al.10 National Comorbidity Study (NCS) 
A large staff–model health maintenance organization 
The U.S. Bureau of the Census 
Professional associations and news periodicals 
National Center for Health Statistics 
Industry sources 
  
Goetzel et al.11 Health and Productivity Management (HPM)a Subset of 
MedStat’s MarketScanb Database 
  
Andlin-Sobocki13 German National Health Interview and Examination 
Survey - mental health supplement (GHS–MHS)c 
  
Marciniak et al.15  Health and Productivity Management (HPM) Subset of 
MedStat’s MarketScan Database 
  
McLaughlin et al.20  PharMetrics Patient-Centric Databased 
  
Stein et al.21 Integrated Healthcare Information Services National 
Managed Care Benchmark Databasee 
 
a The HPM database contains workplace absence, short-term disability, and worker 
compensation data for six fortune 200 U.S. employers. 
b The Market- Scan database is an annual medical database that includes private sector 
health data from approximately 100 payers and contains data on clinical utilization, 
expenditures, and enrollment across inpatient, outpatient, prescription drug, and carve-out 
services. This database links paid claims and encounter data to detailed patient 
information across sites and types of providers over time. 
c The survey was carried out in 1998/99 and included a community sample of 4181 (age: 
18–65) individuals. 
d PharMetrics Patient-Centric database is composed of medical and pharmaceutical 
claims for approximately 36 million patients from 61 health plans across the United 
States. 
e Located in Waltham, Massachusetts, this nationally representative database includes 
data from 30 health plans covering more than 25 million persons. 
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 Perspective of the study. Eight out of twenty one studies used payer 
perspective,11,15-17,19-22 while other studies used societal perspective. 
 
 Cost categories. More than half of the studies included indirect costs in their 
analysis as well as direct costs. To estimate indirect costs, all studies used HCA. Only 
four studies gave an estimation of indirect costs on a population level (employed or 
unemployed patients).5,13,29,43 The rest reported indirect costs based on employed patients 
only.10,11,14,15,24-28 Specific cost categories used in these studies are shown in Table 2-3.44 
As one can see, the most frequent cost categories included in the analysis were outpatient 
treatment cost, costs for hospital treatment, drugs, and emergency room facilities. Studies 
conducted by DuPont et al.5 and Greenberg et al.10 were the most comprehensive studies 
with respect to cost categories included in the analysis. 
 
 Incremental cost approach. In estimating the cost of illness for anxiety 
disorders, less than half of the studies calculated the incremental healthcare cost of 
individuals with anxiety disorders, in excess of those who were anxiety free. In other 
words, not only costs directly due to anxiety disorders were included, but also costs due 
to comorbidities and complications of anxiety disorders were considered in their cost 
estimation;14,15,17,18,20,22,24,27,29 Rest of the studies only estimated the costs which were 
directly due to anxiety disorders.  
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Table 2-3. Cost categories included in cost of illness studies.  
 
 
ER = Emergency Room. 
Source: Konnopka A, Leichsenring F, Leibing E, Konig HH. Cost-of-illness studies and 
cost-effectiveness analyses in anxiety disorders: a systematic review. Journal of Affective 
Disorders. Apr 2009; 114(1-3):14-31. 
  
  Direct costs  Indirect costs 
 
O
utpatient 
Inpatient 
M
edications 
R
ehabilitations 
E
R
 
N
on-m
edical 
Productivity loss 
Sick-leave 
E
arly retirem
ent 
M
ortality 
Authors 
Edlund and Sawn43  ?        ?   
Siegel et al.24  ?    ?    ?   
Souetre et al.25  ? ? ?  ?    ?   
Salvador-Carulla et al.26  ? ? ?      ?   
DuPont et al.5  ? ? ? ? ? ?  ? ? ? ? 
Leon et al.16  ?           
Rees et al.17  ?   ?        
Greenberg et al.10  ? ? ?  ? ?  ? ? ? ? 
Patel et al.27  ? ? ?      ?   
Goetzel et al.11  ? ? ? ? ?       
Marciniak et al.15  ? ? ?      ?   
Marciniak et al.18  ? ? ?         
Andlin-Sobocki et al.13  ? ? ? ? ?    ?   
Panzer et al.19  ? ? ?  ?       
Roberge et al.23  ?  ?         
McLaughlin et al.20  ? ? ?  ?       
Smit et al.14  ? ? ? ? ? ?   ?   
Stein et al.21  ? ? ?  ?       
Batelaan et al.28  ? ? ? ? ? ?   ?   
Olfson and Gameroff 22  ? ?   ?       
Acarturk et al.29  ? ? ?   ?  ?    
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CHAPTER 3.    METHODOLOGY 
 
 
Research Design 
 
 In order to estimate the cost of illness for anxiety disorders, a retrospective 
database analysis was conducted. The specific features of the research are as follows: 
 
 
Perspective 
 
 Cost of illness for anxiety disorders was calculated from a societal perspective. In 
other words, this economic evaluation includes the impact of anxiety disorders on the 
welfare of the whole society. In order to achieve this goal, both direct and indirect costs 
attributable to anxiety disorders have been estimated. The costs components included in 
this study are as follow: 
 
? Direct medical costs: This category refers to expenditures for inpatient visits, 
outpatient visits, office-based medical provider visits, emergency room visits, 
prescription medications, and other medical expenses (other medical expenses 
refer to expenses not included in the above-mentioned categories, such as 
expenditures for home health and medical devices and supplies). 
 
? Indirect costs: This category includes morbidity and mortality costs. 
 
 
Approach 
 
 To estimate cost of illness, one can take either incidence-based or prevalence-
based approach. As it was mentioned in the previous chapter, prevalence-based approach 
is far more common, since it needs less data and time in comparison with the incidence-
based one. So in this research, a prevalence-based approach was adopted to estimate the 
cost of illness for anxiety disorders. 
 
 
Data 
 
 Data was collected from three major databases. These databases are explained in 
details in the “Data Overview” section. 
 
? Medical Expenditures Panel Survey (MEPS). 
 
? The Bureau of Labor Statistics (BLS). 
 
? The National Vital Statistics System (NVSS).  
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 Table 3-1 shows the exact databases used for calculation of each cost component. 
Using these databases, the researcher estimated costs at individual level. The bottom-up 
approach was undertaken to aggregate individual-level data to population-level. 
 
 
Sampling 
 
 MEPS sampling plan. The study sample was based on the MEPS sampling plan. 
As it was mentioned in chapter 2, MEPS collects data on health services utilization and 
cost, as well as how frequently these services are used and how they are paid.45  
 
MEPS currently has two major components: the Household Component and the 
Insurance Component. The Household Component provides data from individual 
households and their members, which is supplemented by data from their medical 
providers. The Insurance Component is a separate survey of employers that 
provides data on employer-based health insurance. The Household Component 
(HC) collects data from a sample of families and individuals in selected 
communities across the United States, drawn from a nationally representative 
subsample of households that participated in the prior year's National Health 
Interview Survey (conducted by the National Center for Health Statistics). During 
the household interviews, MEPS collects detailed information for each person in 
the household on demographic characteristics, health conditions, health status, use 
of medical services, charges and source of payments, access to care, satisfaction 
with care, health insurance coverage, income, and employment.45  
 
 
Table 3-1. Data sources for calculation of each cost component. 
 
Cost component Data source 
Direct Medical Cost MEPS Data Files including: 
Full Year Consolidated Data File 
Medical Conditions File 
Prescribed Medicines File 
Hospital Inpatient Stays File 
Emergency Room Visits File 
Outpatient Visits File 
Office-based Medical Provider File 
Home Health Services File 
Other Medical Expenses File 
  
Indirect cost: Morbidity MEPS Full Year Consolidated Data File 
Bureau of Labor Statistics (BLS) 
  
Indirect cost: Mortality The National Vital Statistics System (NVSS) 
Bureau of Labor Statistics (BLS) 
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 In this study, only the household component has been used. Each year, the 
selected households from the prior year's National Health Interview Survey (NHIS) form 
a panel. Each panel is followed for a period of two years. During these two years, each 
household in the panel is interviewed in five rounds. Consequently, the sample for each 
year of the MEPS data files includes two overlapping panels. Figure 3-1 shows this 
overlapping panel design.46 
 
 Sample size. When using national data, a sufficient sample size must be obtained 
to ensure reliable survey estimates; Medical expenditure data are highly skewed. It means 
that a small portion of population accounts for a large portion of expenses. Medical 
expenditure data from MEPS follow the same pattern. Consequently, if the sample size is 
not large enough, “some point estimates for particular subgroups of the population may 
show substantial fluctuations from one year to the next that are not statistically 
significant.”47(p. 2615) To address this issue, the Agency for Healthcare Research and 
Quality (AHRQ) has set the minimum requirement of 100 un-weighted participants per 
cell for producing national estimates.47 
 
 Even though MEPS annual sample size is much larger than 100, the number of 
participants in many of the MEPS analytic and policy relevant subpopulations of interest 
might be less than 100. Fortunately, several consecutive years of MEPS data files can be 
pooled together to improve the precision of estimates and expand the types of analyses 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1. Overlapping design of MEPS sample. 
 
Source: MEPS HC-138: 2010 Full Year Consolidated Data File. 2012; 
http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h138/h138doc.shtml#2581
UnitedStates. Accessed 10/15/2012. 
1/1/2011 1/1/2010 
Panel 14 
Round 1 Round 2 Round 3 Round 4 Round 5 
Panel 15 
Round 1 Round 2 Round 3 Round 4 Round 5 
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possible. 
 
 For this research, data was pooled from the 2009-2010 MEPS public use files, to 
allow for a large enough sample size. 2009 and 2010 data were the latest available MEPS 
datasets at the time of study. More specifically, data files used in this study were: full 
year consolidated data file; medical conditions file; as well as event level files for 
prescribed medicines, hospital inpatient stays, emergency room visits, outpatient visits, 
office-based medical provider visits, home health visits, and other medical expenses from 
2009 and 2010 MEPS-Household Components. The pooling was conducted according to 
the MEPS guidelines on pooling several years of data.48 
 
 Study sample. The study population is consisted of all survey-respondents (for 
the years 2009 and 2010) 18 years and older, with positive person weights. Among these, 
individuals who reported a diagnosis of, or had a medical event associated with anxiety 
disorder(s) were classified as anxiety patients. Diagnoses and events were identified 
using Clinical Classification (CC) code. CC code aggregates conditions and procedures 
into mutually exclusive and clinically homogeneous categories, using Clinical 
Classification Software.49 The CC code 651 is specifically assigned to anxiety disorders. 
The conditions included in this category are: generalized anxiety disorder, panic disorder, 
phobias (social phobia, specific phobia), agoraphobia, obsessive-compulsive disorder, 
post-traumatic stress disorder, acute stress disorder, overanxious disorder, and mixed 
emotional disturbances. 
 
 
Data Overview 
 
 As it was mentioned earlier, three major databases were used in this study as data 
sources. Information collected from each of these data bases is provided in the following 
sections: 
 
 
MEPS Data Files 
 
 The majority of data was collected from MEPS: 
 
MEPS is a set of large-scale surveys of families, individuals, their medical 
providers and employers across the United States. It is jointly sponsored by the 
Agency for Healthcare Research and Quality (AHRQ) and the National Center for 
Health Statistics (NCHS), and has been conducted annually since 1996. It has 
three major components; the Household Component (HC), the Insurance 
Component (IC), and the Medical Provider Component (MPC). The MEPS-HC 
collects data from a nationally representative sample of the civilian non- 
institutionalized population of the U.S.; and is intended to provide national 
estimates of healthcare utilization, cost, insurance cover- age, and sources of 
payment.50(p. 721) 
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 The following MEPS data files were used in this research: 
 
? Full Year Consolidated Data file: Each year, the Full Year Consolidated Data file 
provides information collected on a nationally representative sample of the 
civilian non-institutionalized population of the United States for that calendar 
year. More specifically, this file contains the following variables: survey 
administration, language of interview, demographics, parent identifiers, health 
status, disability days, access to care, employment, quality of care, patient 
satisfaction, health insurance, use, income, and expenditure variables. 
 
? Medical Conditions file: For each calendar year, the Medical Conditions file 
provides information on household-reported medical conditions. 
 
? MEPS Household Component Event files: There are seven event-level files in 
MEPS Household Component which provide information on utilization and 
expenditure, due to medical conditions, by type of health services received. These 
files are: Prescribed Medicines file, Dental Visits file (not used in this study), 
Other Medical Expenses file, Hospital Inpatient Stays file, Emergency Room 
Visits file, Outpatient Visits file, Office-Based Medical Provider Visits file, and 
Home Health file. 
 
 Variables used in analyses from MEPS data files. List of variables from these 
data files, which were used in the analyses, are provided in Table 3-2. Some of these 
variables are categorical while others are continuous. List of categorical variables, along 
with levels of each variable, is provided in Table 3-3.  
 
 Summary variables. According to the MEPS survey design, each year 
interviewers collect data through three consecutive rounds (for each panel). Consequently 
for most measures, MEPS has information in each round (round-level variables) and also 
at the end of year. However, some variables are presented only at round-level and the 
researcher needs to summarize them into single variables representing the status of a 
whole year. In this section, list of summary variables used in the analyses and the way 
they were constructed are provided. 
 
? Perceived health status (RTHLTH), Sick-leave pay (SICPAY), union status 
(UNION), and occupation category (OCCCAT): The value of summery variable 
would be equal to the most frequent value of round variables. If round variables 
all have different values, then round variable with the longest reference period 
represents the summery variable.  
 
? Number of days missed work due to illness/injury (DDNWRK) and number of 
days stayed in bed due to illness/injury (DDBDYS): Summery variable is equal to 
the sum of round-level variables. 
 
? Employment status (EMPST): In MEPS, a current main job is defined for persons 
who either reported they were currently employed and identified a current main 
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Table 3-2. List of variables in MEPS data files used in the current study. 
 
Variable name Description Source 
DUPERSID Person ID Consolidated Data File 
PANEL Panel Number Consolidated Data File 
PERWT10F Final Person Weight,  Consolidated Data File 
VARSTR Variance Estimation Stratum  Consolidated Data File 
VARPSU Variance Estimation PSU Consolidated Data File 
SEX Sex Consolidated Data File 
AGELAST Person’s Age Last Time Eligible Consolidated Data File 
RACEX Race Consolidated Data File 
HISPANX Hispanic Ethnicity Consolidated Data File 
HIDEG Highest Degree Attained Consolidated Data File 
POVCAT10 Family Income as Percent of Poverty Line Consolidated Data File 
MARRY10X Marital Status Consolidated Data File 
REGION10 Census Region  Consolidated Data File 
MSA10 MSA Status  Consolidated Data File 
RTHLTH31 Perceived Health Status RD 31* Consolidated Data File 
RTHLTH42 Perceived Health Status RD 42* Consolidated Data File 
RTHLTH31 Perceived Health Status RD 53* Consolidated Data File 
TOTEXP10 Total Healthcare Expenditure   Consolidated Data File 
ERTEXP10 Total ER Expenditure  Consolidated Data File 
OPTEXP10 Total Outpatient Expenditure  Consolidated Data File 
OBVEXP09/10 Total Office-Based Visits Expenditure  Consolidated Data File 
IPTEXP10 Total Hospital Inpatient Expenditure  Consolidated Data File 
RXEXP10 Total RX Expenditure  Consolidated Data File 
OTHEXP10 Total Equipment/Supply Expenditure Consolidated Data File 
HHNEXP09/10 Total Home Health Non-Agency 
Expenditure 
Consolidated Data File 
HHAEXP09/10 Total Home Health Agency Expenditure Consolidated Data File 
DDNWRK31 # Days Missed Work RD 31 * Consolidated Data File 
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Table 3-2. (Continued). 
 
Variable name Description Source 
DDNWRK42 # Days Missed Work RD 42 * Consolidated Data File 
DDNWRK53 # Days Missed Work RD 53 * Consolidated Data File 
WKINBD31 # Days Stayed in Bed RD 31 * Consolidated Data File 
WKINBD42 # Days Stayed in Bed RD 42 * Consolidated Data File 
WKINBD53 # Days Stayed in Bed RD 53* Consolidated Data File 
EMPST31 Employment Status RD 31* Consolidated Data File 
EMPST42 Employment Status RD 42* Consolidated Data File 
EMPST53 Employment Status RD 53* Consolidated Data File 
HRWG31X Hourly Wage RD 31 * Consolidated Data File 
HRWG42X Hourly Wage RD 42 * Consolidated Data File 
HRWG53X Hourly Wage RD 53 * Consolidated Data File 
SELFCM31 Self-Employed RD 31 * Consolidated Data File 
SELFCM42 Self-Employed RD 42 * Consolidated Data File 
SELFCM53 Self-Employed RD 53 * Consolidated Data File 
UNION31 Union Status RD 31 * Consolidated Data File 
UNION42 Union Status RD 42 * Consolidated Data File 
UNION53 Union Status RD 53 * Consolidated Data File 
SICPAY31 Paid Sick Leave RD 31* Consolidated Data File 
SICPAY42 Paid Sick Leave RD 42* Consolidated Data File 
SICPAY53 Paid Sick Leave RD 53 * Consolidated Data File 
NUMEMP31 Number of Employees RD 31 * Consolidated Data File 
NUMEMP42 Number of Employees RD 42 * Consolidated Data File 
NUMEMP53 Number of Employees RD 53 * Consolidated Data File 
OCCCAT31 Occupation Group RD 31 * Consolidated Data File 
OCCCAT42 Occupation Group RD 42 * Consolidated Data File 
OCCCAT53 Occupation Group RD 53 * Consolidated Data File 
INS10X Insurance Indicator Variable Consolidated Data File 
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Table 3-2. (Continued). 
 
Variable name Description Source 
INSCOV10 Health Insurance Coverage Indicator  Consolidated Data File 
MCAID10X Covered by Medicaid Consolidated Data File 
MCARE10X Covered by Medicare Consolidated Data File 
TRICR10X Covered by Tricare Consolidated Data File 
OTPUBA10, 
OTPUBB10, 
STAPR10 
Covered by Other Public Insurances Consolidated Data File 
PUB10X Covered by Public Insurance Consolidated Data File 
CONDIDX Condition ID Medical Conditions 
File 
ICD9CODX ICD-9-CM Code For Condition  Medical Conditions 
File 
CCCODEX CC Code in Conditions File Medical Conditions 
File 
RXCCC1X-3X CC Code in RX File RX File 
ERCCC1X-3X CC Code in ER Visit File ER visits File 
OPCCC1X-4x CC Code in Outpatient Visit File Outpatient Visits File 
IPCCC1X-4X CC Code in Hospital Inpatient File Hospital Inpatient File 
OBCCC1X-4X CC Code in Office-Based Visit  File Office-Based Visits 
File 
 
Notes: Name of variables in this table are as shown in MEPS 2010 data files. In the 
previous years of MEPS data files, most variables have the same names. Variables ending 
in 10 represent the values as of 12/31/2010. So for each year of data collection, these 
variables would end in XX, where XX are the last two digits of the year data was 
collected for; Variables ending in 31, 42, or 53 are round specific variable and the last 
two digits at the end specify the round in which data was collected (i.e. round 1, 2, 3 of 
the panel started in the current year (the first digit) or round 3, 4, 5 of the panel started in 
the previous year (the second digit)).  
* These variables haven’t been used directly in the analyses. Instead, they have been used 
to construct summary variables, and the summary variables were included in the 
analyses.  
PSU=Primary Sampling Unit; MSA = Metropolitan Statistical Area; RD = Round; ER = 
Emergency Room; RX = Prescribed Medicine; # = Number; CC = Clinical Classification. 
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Table 3-3. List of categorical variables. 
 
Variable(s) Level Value 
Sex 1 Male 
2 Female 
   
AGE CATEGORYa 1 18-24 
2 25-44 
3 45-64 
4 65+ 
   
RACE/ETHNICITYb 1 White-non Hispanic 
2 Black-non Hispanic 
3 Hispanic 
4 Other 
   
REGION10 1 Northeast 
2 Midwest 
3 South 
4 West 
   
MSA10 1 Non-MSA 
2 MSA 
   
POVCAT10 
(Poverty Category) 
1 Poor 
2 Near poor 
3 Low income  
4 Middle income 
5 High income  
   
MARRY10X 
(Marital Status) 
1 Married 
2 Widowed/Divorced/Separated 
3 Never Married 
   
INSCOVc 
(Insurance Coverage) 
1 Uninsured 
2 Dual Eligible 
3 Medicare 
4 Medicaid 
5 Other Public 
6 Private 
   
SELFCM  
UNION 
SICPAY 
1 Yes 
2 No 
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Table 3-3. (Continued). 
 
Variable(s) Level Value 
EMPST31/42/53 
(Employment Status) 
1 Currently employed 
2 Has a job to return to 
3 Employed during the reference period 
4 Not employed with no job to return to 
   
OCCCAT 
(Occupation Category) 
1 Management, business, and financial operations 
2 Professional and related occupations 
3 Service occupations 
4 Sales and related occupations 
5 Office and administrative support 
6 Farming, fishing, and forestry 
7 Construction, extraction, and management 
8 Production, Transportation, and material moving 
   
HIDEG 
(Education) 
1 No degree 
2 GED/High school diploma 
3 Bachelor’s degree 
4 Master/PhD 
5 Other degree 
   
RTHLTH 
(Perceived Health Status) 
1 Excellent 
2 Very good 
3 Good 
4 Fair 
5 Poor 
   
CCIfreq 
(D’Hoore Adaptation of 
Charlson Comorbidity 
Index)d 
0 Zero comorbidity 
1 One comorbidity 
2 Two comorbidities 
3 Three or more comorbidities 
 
Note: The levels reported for some categorical variables here, do not exactly match the 
levels originally provided in MEPS data files. For some variables, we had to combine two 
or more levels to summarize data, or to get enough sample size in each level. 
a This variable was constructed using the continues variable “AGELAST”; b This variable 
was constructed using “RACEX” and “HISPANX” variables; c This variable was 
constructed using the following variables: INS10X, INSCOV10, MCAID10X, 
MCARE10X, TRICR10X, OTPUBA10, OTPUBB10, STAPR10, and PUB10X; d This 
variable was constructed using ICD-9-CM cods, according to the conditions and weights 
listed in the D’Hoore adaptation of CCI.  
GED = Graduate Equivalency Degree; MSA = Metropolitan Statistical Area. 
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job (at the time of interview), or those who reported and identified a job to return 
to. So, If an individual had a current main job for at least one round in year (at 
least one of the round-level variables was equal to 1 or 2), then he/she was 
considered as being employed (EMPST=1). 
 
? Hours worked per week (HOUR), number of employees (NUMEMP), and hourly 
wage (HRWG): Summery variable is equal to the mean of round-level variables. 
 
? Self- employment status (SELFCM): For employed individuals, If at least in one 
of the reported current main jobs, the person was self-employed, he/she is 
considered as self-employed (SELFCM=1). 
 
 
BLS Data  
 
 “The Bureau of Labor Statistics (BLS) is an independent national statistical 
agency that collects, processes, analyzes, and disseminates essential statistical data to the 
American public, the U.S. Congress, other federal agencies, state and local governments, 
business, and labor. The BLS also serves as a statistical resource to the Department of 
Labor.”51 Examples of information that BLS provides are: employment cost trends, 
national compensation data, wages by area and occupation, earnings by demographics, 
earnings by industry, employee benefits … 
 
 The specific information collected from BLS is: 
 
? Weekly & Hourly Earnings:52 The BLS reports (median) weekly earnings by 
industry type, occupation type, sex, race, ethnicity, age, education level, class of 
worker and labor force status. This information is based on the Current Population 
Survey (CPS).The CPS is a monthly survey of households (the sample represents 
the civilian non-institutional population of the U.S.) conducted by the Bureau of 
Census for the BLS. It provides a comprehensive body of data on the labor force, 
employment, unemployment, persons not in the labor force, hours of work, 
earnings, and other demographic and labor force characteristics.  
 
? Labor Force Statistics:53 The data contains Labor Force Participation Rate (LFPR) 
by age, race, and gender. This information is also based on the CPS. 
 
? Healthcare component of the Consumer Price Index(CPI) as well as CPI for all 
items: This information is available in the CPI Detailed Report Data for March 
2013.54  
 
 
NVSS Data 
 
 The National Center for Health Statistics (NCHS) is a component of the Centers 
for Disease Control and Prevention (CDC), and “its mission is to provide statistical 
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information that will guide actions and policies to improve the health of the American 
people. To carry out its mission, NCHS conducts a wide range of annual, periodic, and 
longitudinal sample surveys and administers the National Vital Statistics Systems.”55 The 
NVSS collects data on vital events including  births, deaths, marriages, and divorces in 
the United States. The researcher used the following reports to collect required data. 
Number of deaths due to anxiety disorders were extracted from the first three reports, 
while the fourth one was used to collect information on life expectancy. 
 
? Deaths, percent of total deaths, and death rates for the 15 leading causes of death 
in 5-year age groups, by race and sex: United States, 1999-2010.56 
 
? Deaths, percent of total deaths, and death rates for the 15 leading causes of death 
in 10-year age groups, by Hispanic origin, race for non-Hispanic population and 
sex: United States, 2010.57 
 
? Deaths, percent of total deaths and rank order for 113 selected causes of death and 
Enterocolitis due to Clostridium difficile, by Hispanic origin, race for non-
Hispanic origin and sex, United States, 2010.58 
 
? Deaths: Final data for 2010.59 
 
 
Analysis Technique 
 
 In this section, the analysis technique for each specific aim of the study is 
explained. 
 
 
SA1: Estimating the Societal Cost of Anxiety Disorders for the U.S. Adult 
Population 
 
 According to Equation 3-1, the societal cost of anxiety disorder(s) is equal to 
summation of its direct and indirect costs. 
 
Total cost = Overall direct medical cost + Indirect cost (Eq. 3-1) 
 
 In the following sections, the methodology used to estimate each component of 
Equation 3-1 is explained. 
 
 Overall direct medical cost. Overall direct medical cost incorporates costs due to 
prescription medications, office-based medical provider visits, inpatient visits, outpatient 
visits, ER visits, and other medical expenses. In this section, we explain the methodology 
used to estimate the overall direct medical costs due to anxiety disorders. Estimating 
direct medical cost by category of health service (SA2), is explained in the next section. 
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 To estimate overall direct medical expenditures attributable to anxiety disorders, 
we used the incremental cost approach. This method, suggested by the AHRQ for 
estimating cost of illness with MEPS data, has been widely used by previous 
researchers.60-66 The incremental cost approach provides an estimate of disease-
attributable expenses by calculating expenditures incurred by a disease population in 
excess of those incurred by a disease free population. This difference in expenses by the 
two populations represents the total cost of illness, including treatment expenses, as well 
as expenses related to complications of the disease and its comorbidities.65 To adjust for 
potential differences in socioeconomic and clinical characteristics of the two populations, 
which are considered to have an impact on cost, a multivariate regression analysis is 
conducted. As such, this approach estimates expenditures solely associated with the 
disease of interest.64 
 
 To estimate direct medical costs associated with anxiety disorders, first an 
appropriate multivariate regression analysis needed to be developed to explain healthcare 
costs through a set of explanatory variables. The outcome variable of the model was the 
overall healthcare expenditure. Expenditure (cost) refers to what is actually paid for 
healthcare services and is defined as the sum of direct payments by different sources such 
as out-of-pocket payments, as well as payments by private insurance, Medicaid, and 
Medicare. Expenditures are more accurate than charges for cost estimation purposes. 
Charges vary from what is actually paid, due to uncollected liability, bad debt, charitable 
care, and implementing contract negotiations.46 
 
 The main explanatory variable of the model was a disease- indicator variable, 
indicating whether each individual in the sample suffered from anxiety disorder(s) or not. 
Other covariates of the model were respondents’ gender, age, race/ethnicity, marital 
status, education, poverty category, geographic region, metropolitan statistical area 
(MSA), perceived health status (PHS), health insurance coverage, and the D’Hoore 
adaptation of Charlson Comorbidity Index (CCI). The D’Hoore adaptation of CCI 
controls for 17 medical conditions which are myocardial infarct, congestive heart failure, 
peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary 
disease, connective tissue disease, ulcer disease, mild liver disease, hemiplegia, moderate 
or severe renal disease, diabetes , any tumor, leukemia, lymphoma, moderate or severe 
liver disease, and metastatic solid tumor.67 These covariates were selected based on the 
literature review and the availability of data in MEPS. 
 
 After developing and running the regression model, the estimated coefficients of 
the model were used to calculate two predicted expenses for each individual. The first 
predicted expenses assumed the individual had anxiety disorder(s) (by setting the disease-
indicator variable to one), and the second predicted expenses assumed the individual was 
anxiety-free (by setting the disease-indicator variable to zero). The average per-person 
increase in medical expenses attributable to anxiety disorders was calculated by taking 
the difference in predicted expenses for each person and computing the weighted average 
of the difference across the entire sample. Finally, the average per-person increase in 
expenses was multiplied by the weighted number of individuals with anxiety disorders in 
the sample, to get the total medical cost of anxiety disorders. 
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 In modeling healthcare cost data, the specific distributional characteristics of the 
data must be taken into consideration. These characteristics are: (1) non-negative 
observations; (2) excessive zero (i.e. there are a large number of individuals with zero 
cost); and (3) highly skewed data (i.e. the majority of cost is incurred by a few patients).68 
These characteristics make traditional Ordinary Least Square (OLS) regression inefficient 
in modeling healthcare cost data. Alternatively, OLS with natural log-transformed cost 
has been widely used to deal with heavily skewed data. However, this approach has some 
limitations as well.68 First, the outcome variable is the logarithm of cost. So in order to 
draw useful conclusions about the cost, the predicted values need to be retransformed 
back to the original scale. While retransforming the outcome variable, by using smearing 
factor, seems straightforward, interpretation of parameter estimates may still be 
challenging. Second, in the presence of heteroskedasticity, using one smearing factor to 
retransform the predicted values leads to biased estimates, i.e. under-estimation or over-
estimation of the actual cost. In such scenarios, a Generalized Linear Model (GLM), with 
appropriate variance and link functions, is more efficient to model cost data. GLM 
directly models both the variance and mean functions on the original scale of dependent 
variable. As such, results can be interpreted with no need for retransformation from log 
scale to the original scale.68 “The mean function, E(y|x) is represented as μ(x?β), where μ 
is the inverse link between the expectation of the observed raw-scale y and the linear 
predictor x?β.”68(p. 529) The link function generally used with healthcare cost data is the 
log-link function.68 “Then μ is the exponential function. A commonly used family of 
variance functions includes the power functions of the form v(x) = ? (μ(x?β))λ.”68(p. 529) 
The specific type of variance functions depends on the value of λ. for instance, if the λ is 
equal to 1 it means that variance is proportional to meant. So, it would be a Poisson like 
model If the λ is equal to 2, it means that variance is proportional to mean squared, as in a 
Gamma-like model.68 
 
 In order to find out which type of regression model was most appropriate for our 
data, several diagnostics tests needed to be performed. First of all, we needed to find the 
distribution of cost data to see if data was really skewed or not. Then, appropriateness of 
using OLS regression with log-transformed data needed to be examined. This was 
achieved by conducting the Breusch-Pagan/Cook-Weisberg test for heteroskedasticity. 
One of the assumption of OLS is that variance of error terms (εj) should be constant (εj = 
?2; for all j). If this assumption is violated, i.e. when heteroskedasticity is present, OLS 
estimates are no longer the best linear unbiased estimator (BLUE). One of the major 
consequences of heteroskedasticity is biased standard errors, in which leads to biased 
inference, so results of hypothesis tests are possibly wrong. The Breusch-Pagan/Cook-
Weisberg test for heteroskedasticity tests the linear heteroskedasticity.69 Their null and 
alternative hypotheses are as follows: 
 
 H0: error variances are all equal 
 H1: error variances are a multiplicative function of one or more variables 
 
 In the case that heteroskedasticity was present; we needed to conduct a Park test 
to see which variance function was more appropriate to be used in the context of GLM. 
Park test was first introduced by Park in 1966, and its use is suggested in estimation of 
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the relationship between the mean and the variance.68,70 In this regard, “the squared 
residuals from a provisional model (GLM or log-transformed OLS) should be regressed 
on the predictions (ŷ) from the same model, both log transformed.”68(p. 531) Equation 3-2 
shows the regression model for Park test: 
 
ln ((yi- ŷi)2) = λ0 + λ1 ln (ŷi) + ?I (Eq. 3-2) 
 
Source: untin MB, Zaslavsky AM. Too much ado about two-part models and 
transformation?: Comparing methods of modeling Medicare expenditures. Journal of 
Health Economics. 5// 2004;23(3):525-542. 
 
 Morbidity cost. Indirect cost due to productivity loss (morbidity cost), have been 
measured using the Human Capital Approach (HCA). In the HCA, productivity loss due 
to an illness or injury is approximated by valuing the entire period of absence from work 
by average individual’s earning. Equation 3-3 shows the formula used to estimate the 
morbidity cost due to anxiety disorders: 
 
Morbidity Cost ? ?? ????? ??????
?
???
? ???????
? ? ???? (Eq. 3-3) 
 
Where: 
N = Total number of individuals in the sample. 
Wti = Person weight for the ith individual in the sample. 
Wgi = Daily wage for employed individuals and average daily wage for household 
services if the individual is not employed. 
ni = Number of missed work days (due to anxiety disorders) for employed individuals and 
number of days stayed in bed (due to anxiety disorders) for unemployed individuals. 
Nanx = Weighted number of individuals in the sample with anxiety disorder(s). 
 
 For individuals who were at paid employment for at least on round in year, 
information on wage rates are available in the MEPS (in both Consolidated Data file and 
Job file). For unemployed individuals, the period in which they had to stay in bed due to 
an illness or injury was valued by average wage for private household services. Industries 
in the private households are defined as those “engage in employing workers on or about 
the premises in activities primarily concerned with the operation of the household. These 
private households may employ individuals, such as cooks, maids, butlers, and outside 
workers, such as gardeners, caretakers, and other maintenance workers.”71 Average wage 
for private household services was obtained from the BLS. 
 
 Information on number of missed-work-days for employed individuals, (and 
number of days an unemployed person had to stay in bed) due to each particular 
condition, is not available in MEPS. Instead, MEPS collects this information for all 
medical conditions an individual might have had in the survey year. So, we needed to 
find out what portion of missed-work-days (variable WKINBD in MEPS consolidated 
data file) and bed days (variable DDBDYS) were due to anxiety disorders. In this regard, 
researcher used the same approach used to estimate the incremental cost. In other words, 
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two separate multivariate regression analyses were conducted to estimate the incremental 
number of missed work days/ bed days due to anxiety disorders. This approach has been 
used by Akazawa, Sindelar, and Paltiel in their research on estimating the productivity 
loss due to Influenza related illnesses.72 
 
 Outcome variables and the initial set of covariates for estimating the incremental 
number of work days/ bed days due to anxiety disorders are provided in Table 3-4. These 
covariates have been selected based on the relevant literature and availability of data in 
MEPS. 
 
 After developing and running regression models, the estimated coefficients of 
each model were used to calculate two outcomes for each individual. The first predicted 
outcome assumed the individual had anxiety disorder(s) (by setting the disease-indicator 
variable to one), and the second predicted outcome assumed that the individual was 
anxiety-free (by setting the disease-indicator variable to zero). The per-person increase in 
number of missed work days/ bed days attributable to anxiety disorders were calculated 
by taking the difference in predicted outcomes for each person. Morbidity cost for each 
individual in the study sample (per-person morbidity cost) was calculated by multiplying 
the predicted outcome (i.e. predicted number of missed work days due to anxiety 
disorders if the person was employed, and predicted number of bed days due to anxiety 
disorders if the person was not employed), by the average daily wage of that person.  
 
 
Table 3-4. Outcome variables and the initial set of covariates for estimating the 
incremental number of missed work days/ bed days due to anxiety disorders. 
 
Regression 
model 
Outcome 
variable 
Sample for regression 
analysis Initial set of covariates 
Model 1 WKINBD Employed individuals in 
the study population 
(excluding self-
employed persons)a 
anx,b gender, race/ethnicity, 
age, marital status, education, 
poverty category, insurance 
coverage, MSA, region, CCI, 
number of employees, sick-
pay, union status, occupation 
category   
    
Model 2 WKINBD Unemployed individuals 
in the study population 
anx, gender, race/ethnicity, 
age, marital status, education, 
poverty category, insurance 
coverage, MSA, region, CCI. 
 
a Self-employed individuals were excluded, since information such as sick-pay benefit is 
not available for them. 
b anx represents the disease indicator variable. 
MSA = Metropolitan Statistical Area, CCI = Charlson Comorbidity Index. 
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 Average morbidity cost was estimated by taking the weighted mean of per-person 
morbidity cost across the entire study sample. Finally, this average per-person cost was 
multiplied by the weighted number of individuals with anxiety disorders in the sample to 
get the total morbidity cost associated with anxiety disorders. 
 
 Mortality cost. Mortality cost is productivity loss due to premature deaths. In a 
prevalence-based cost of illness study, productivity losses are “calculated for all patients 
who die or become permanently disabled in the study year for that year and each year 
until the expected age of death.”3(p. 9) In the HCA, mortality cost is the present value of 
future earnings, from age of death to life expectancy. Lost future earnings due to a 
medical condition can be estimated knowing the total number of deaths due to that 
condition, and average annual wages of deceased individuals from the year they died to 
their life expectancies.  
 
 In calculating mortality cost, it is assumed that “people will be working and 
productive during their expected lifetime in accordance with the current pattern of work 
experience”73(p. 283) (for their age/sex/race cohort). So, no assumption needed to be made 
about the employment rate among deceased individuals. The researcher instead allowed 
the actual employment experience of each age/sex/race cohort inform the calculations. 
The estimated lifetime earnings (in present value terms) of a 25 year old White woman 
would not be the same as that of a 40 year old Black man, in part because of different 
LFPRs of these two cohorts. The LFPR in the BLS data already accounts for that source 
of difference, so no further explicit assumption or adjustment needed to be made to 
recognize the importance of this factor. LFPR is defined as the ratio of the civilian non-
institutionalized population who are in labor force by the civilian non-institutionalized 
population who are eligible to be in labor force. 
 
 Another point to consider is that wages usually increase as individuals get more 
experienced. So, average annual wage at time of death should be inflated to consider this 
growth. According to BLS, 12-month increase in wages and salaries for the first quarter 
of 2013 was equal to 1.6%.74 So, we assumed an increase of 1.6% in annual wages too. 
Future annual earnings should then be discounted by an appropriate discount rate. The 
most common discount rate used in the relevant literature is 3%, which is recommended 
by the Panel on Cost Effectiveness in Health and Medicine.75 Current value of future 
earnings should be calculated for all individuals who died due to the medical condition, 
in the period of study, and then added up to get the mortality cost. In the case of anxiety 
disorders, the researcher needed to know the number of suicides due to this medical 
condition. It has been shown that 10% of suicides are due to anxiety disorders.5,10 So, we 
multiplied the total number of suicides buy 10% to get the number of deaths. 
 
The formula used to estimate the mortality cost associated with anxiety disorders 
is shown in Equation 3-4. 
 
??? ? ? ????????????
?????????
??
??
????
 (Eq. 3-4) 
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Where:  
MTC = Mortality cost for individuals who committed suicide due to anxiety disorders in 
the period of study. 
Ad= Age of death 
Le= Life expectancy at age of death by race and gender. 
Li= Labor force participation rate by gender and race at age i. 
W= Average annual wage by gender and race at age of death. 
r = Discount rate 
 
 
SA2: Estimating the Incremental Direct Medical Expenditures Associated with 
Anxiety Disorders by Service Category 
 
 Incremental direct medical expenditures associated with anxiety disorders for 
different healthcare delivery settings were also estimated using the incremental cost 
approach. We followed the exact same procedure used for estimating the overall 
incremental cost. More specifically, several multivariate regression analyses were 
developed to separately model inpatient visits expenditure, outpatient visits expenditure, 
emergency room visits expenditure, prescription medications expenditure, office-based 
visits expenditure, and other medical expenses. So for each model, the dependent variable 
was the cost category of interest. Regression analyses were conducted on all individuals 
in the study sample. 
 
 For all models, the same set of covariates was used. The main independent 
variable of the models was the anxiety indicator variable (yes/no). Other covariates 
included respondents’ gender, age, race/ethnicity, marital status, education, poverty 
category, geographic region, metropolitan statistical area (MSA), perceived health status 
(PHS), health insurance coverage, and the D’Hoore adaptation of Charlson Comorbidity 
Index (CCI). 
 
 
SA3: Estimating the Incremental Direct Medical Expenditures Associated with 
Anxiety Disorders for Different Sub-populations 
 
 Incremental direct medical expenditures associated with anxiety disorders were 
estimated for different sub-populations, using the incremental cost approach. These sub-
populations were defined based on gender, age, race/ethnicity, marital status, education, 
poverty category, region, MSA, and insurance coverage. Several multivariate regression 
analyses were conducted to separately model overall healthcare cost for each group of 
individuals. The dependent variable in all models was the overall healthcare cost. To 
estimate the cost in each group, the regression analysis was conducted on that sub-
population only and therefore, the covariate identifying that sub-population was excluded 
from the regression model. For instance, to estimate the incremental cost of anxiety 
disorders among males, the regression analysis was conducted on males, excluding 
gender from covariates of the model.  
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 We broke down the costs among Blacks and Whites even further by gender, age, 
and geographic region (as you will see in the next chapter, cost of anxiety disorders was 
not statistically significant for Hispanics. So, there was no point in looking at the cost of 
anxiety disorders for Hispanics). The specific sub-populations in which incremental costs 
of anxiety disorders were estimated for, along with covariates of each model are provided 
in Table 3-5. 
 
 
General Notes 
 
 For direct medical costs, all dollar amounts have been presented in 2013 dollars, 
using the healthcare component of the CPI (for all urban consumers). Also, for morbidity 
and mortality costs, all dollar amounts have been presented in 2013 dollars, using the CPI 
(for all urban consumers), for all items. The formulas used to present cost data from 
2009/2010 dollars to 2013 dollars are provided below: 
 
$2009 * (CPI2013 / CPI2009) = $2013 
$2010 * (CPI2013 / CPI2010) = $2013 
 
Where: 
$2009 = Cost in 2009 dollars. 
$2010 = Cost in 2010 dollars. 
$2013 = Cost in 2013 dollars. 
 
For direct medical cost: 
CPI2009 = Healthcare Component of CPI for the year 2009 = 379.51654 
CPI2010 = Healthcare Component of CPI for the year 2010 = 391.04654 
CPI2013 = Healthcare Component of CPI for the year 2013 = 424.15454 
 
For morbidity and mortality costs:  
CPI2009 = CPI for all items for the year 2009 = 212.70954 
CPI2010 = CPI for all items for the year 2010 = 217.63154 
CPI2013 = CPI for all items for the year 2013 = 232.77354 
 
 All statistical analyses were conducted using SAS software version 9.3 (SAS 
Institute, Cary, NC)76 and STATA software version 12.77 
 
 All analyses accounted for the complex survey design of MEPS to obtain 
national-level estimates. Furthermore, subpopulation analysis was conducted to generate 
results for individuals 18 years and older. Thereby, all results are projected to the 
ambulatory adult population of the U.S.  
 
 The p-value threshold was set at 0.05 to determine statistical significance of two-
tailed tests. 
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Table 3-5. Sub-populations along with model specifications. 
 
  Covariates 
Sub-population Levelsa 
G
ender 
A
ge 
R
ace/Ethnicity 
M
arital status 
E
ducation 
Poverty cat 
R
egion 
M
SA
 
H
ealth Ins 
PH
S 
C
C
I 
Gender Males, Females   ? ? ? ? ? ? ? ? ? ? 
Age in years 18-24, 24-44, 45-46, 65+  ?  ? ? ? ? ? ? ? ? ? 
Race/ethnicity White-non-Hispanic, Black-non Hispanic  ? ?  ? ? ? ? ? ? ? ? 
Marital Status Married, Previously Married, Never married,   ? ? ?  ? ? ? ? ? ? ? 
Education None, GED/High School Diploma, Bachelor, Master/PHD  ? ? ? ?  ? ? ? ? ? ? 
Poverty Category Poor, Near poor, Low income, Middle income, High income  ? ? ? ? ?  ? ? ? ? ? 
Region Northeast, Midwest, South, West  ? ? ? ? ? ?  ? ? ? ? 
MSA Non-MSA, MSA  ? ? ? ? ? ? ?  ? ? ? 
Insurance Coverage Uninsured, Dual Eligible, Medicaid, Medicare, Other public, 
private only 
 ? ? ? ? ? ? ? ?  ? ? 
Race*Gender White-Male, White-Female, Black-Male, Black-Female   ?  ? ? ? ? ? ? ? ? 
Rage*Age White- 18 to 44, White 45 &more, Black 18 to 44, Black 45 & 
more 
 ?   ? ? ? ? ? ? ? ? 
Race*Region White-Northeast, White-Midwest, White-South, White-West 
Black-Northeast, Black-Midwest; Black-South, Black-West 
 ? ?  ? ? ?  ? ? ? ? 
Race*Gender*Age White – Male- 18 to 44, White – Male- 45 & more 
White – Female- 18 to 44, White – Female- 45 & more 
Black – Male- 18 to 44, Black – Male- 45 & more 
Black – Female- 18 to 44, Black – Female- 45 & more 
 
   ? ? ? ? ? ? ? ? 
 
a To estimate cost for each sub-population, sample includes individuals in that population only; PHS = Perceived Health Status; MSA 
= Metropolitan /statistical Area, CCI = Charlson comorbidity Index; GED = Graduate Equivalency Degree.
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CHAPTER 4.    RESULTS 
 
 
 Results of the current research are provided in this chapter. The first section 
provides descriptive statistics for the study population. In the second section, results of 
estimating direct medical costs associated with anxiety disorders are presented. Morbidity 
and mortality costs attributable to anxiety disorders are provided in third and fourth 
sections, respectively. Finally, summary of results, i.e. societal cost of anxiety disorders, 
is reported. 
 
 Throughout this chapter, all dollar amounts are presented in 2013 dollar values, 
unless otherwise is specified  
 
 
Descriptive Statistics 
 
 
Prevalence of Self-reported Anxiety Disorders in MEPS 
 
 From the total survey respondents in 2009-2010 (n = 66,148), 46,572 (weighted 
sum = 228,987,954) were adults with positive person weights and non-missing values on 
all of the independent variables, and were included in the final analysis. In 2009-2010 
MEPS survey, 8.74% (weighted sum = 20,337,553) of adults (95% CI: 8.32% to 9.17%) 
reported being diagnosed with an anxiety disorder(s). The remaining 91.26% were 
considered as anxiety-free population. 
 
 
Characteristics of the Study Population 
 
 Table 4-1 compares demographic characteristics of individuals with and without 
anxiety disorder(s) in the study population. Compared to adults with no anxiety disorder, 
those who have been diagnosed with this condition were more likely to be female 
(66.15% versus 50.15%; p < 0.001), White-non Hispanic (79.87% versus 66.77%; p < 
0.001), in the age group of 45 to 64 (40.74% versus 34.19%; p < 0.001), and have one or 
more comorbidities (36.48% versus 27.98%; p < 0.001). Alternatively, they were less 
likely to lack insurance (15.30% versus 20.77%; p < 0.001). Also, the mean ± SE of CCI 
score was significantly higher at 0.82 ± 0.03, for sufferers of anxiety, compared to adults 
without anxiety disorders at 0.51 ± 0.01.  
 
 We also compared the two populations based on the 17 comorbidities used in the 
D’Hoore adaptation of the CCI (Table 4-2). In comparison with the anxiety-free 
population, adults with anxiety disorders were more likely to have congestive heart 
failure (1.49% versus 0.94%; p = 0.004), peripheral vascular disease (1.96% versus 
1.28%; p = 0.020), dementia (0.95% versus 0.53%; p = 0.034), chronic pulmonary 
disease (16.02% versus 8.55%; p < 0.001), connective tissue disease (5.19% versus  
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Table 4-1. Comparison of demographic characteristics between adults with and without anxiety disorders. 
 
  Adults (unweighted n=47,388)a  
 Anxiety disorder(s)    (unweighted n=3,610)a  
No anxiety disorder    
(unweighted n=43,778)a  
Characteristics % 95% CI  % 95% CI p-value 
Gender       < 0.001* 
male 33.85 32.10-35.59  49.85 49.29-50.42  
female 66.15 64.41-67.90  50.15 49.58-50.72  
Age in years      < 0.001* 
18-24 8.61 7.18-10.30  13.22 12.65-13.79  
25-44 34.30 31.76-36.84  34.97 33.97-35.98  
45-64 40.74 38.55-42.94  34.19 33.32-35.07  
65 and Older 16.35 14.58-18.13  17.61 16.74-18.49  
Race/ethnicity      < 0.001* 
White non-Hispanic 79.87 77.82-81.92  66.77 64.88-68.65  
Black non-Hispanic 6.97 5.88-8.06  11.92 10.64-13.21  
Hispanic 8.99 7.63-10.36  14.41 12.78-16.04  
Other non-Hispanic 4.17 3.25-5.09  6.90 5.88-7.92  
Marital Status      < 0.001* 
Married 47.02 44.36-49.68  53.80 52.70-54.91  
Previously Marriedb 29.49 27.19-31.80  19.13 18.29-19.96  
Never Married 23.48 21.17-25.79  27.07 26.24-27.90  
Education      < 0.001* 
No Degree 13.09 11.75-14.42  15.88 15.09-16.67  
GED/High School Diploma 52.75 50.21-55.28  48.45 47.50-49.40  
Bachelor 17.60 15.79-19.41  18.10 17.27-18.94  
Master/PhD 7.10 5.83-8.38  9.41 8.71-10.12  
Other Degree 9.46 8.06-10.87  8.16 7.68-8.63  
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Table 4-1. (Continued). 
 
 Adults (unweighted n=47,388)a  
 Anxiety disorder(s)    (unweighted n=3,610)a  
No anxiety disorder    
(unweighted n=43,778)a  
Characteristics % 95% CI  % 95% CI p-value 
Poverty Category       < 0.001* 
Poor 16.53 14.87-18.20  12.18 11.46-12.89  
Near Poor 4.07 3.24-4.89  4.37 4.06-4.67  
Low Income 13.35 11.78-14.93  13.47 12.83-14.12  
Middle Income 32.09 30.18-34.00  30.25 29.42-31.08  
High Income 33.96 31.33-36.58  39.73 38.36-41.10  
Region       < 0.001* 
Northeast 18.34 15.74-20.95  18.48 17.06-19.91  
Midwest 25.54 23.15-27.94  21.41 20.11-22.71  
South 31.38 28.55-34.20  37.14 35.42-38.87  
West 24.74 22.42-27.06  22.97 21.44-24.49  
MSA       0.901 
Non-MSA 16.00 12.62-19.38  15.85 13.35-18.35  
MSA 84.00 80.62-87.38  84.15 81.65-86.66  
Insurance Coverage       < 0.001* 
Uninsured 15.30 13.53-17.06  20.77 19.72-21.81  
Dual eligiblec 4.57 3.59-5.55  2.08 1.84-2.31  
Medicaid 10.15 8.73-11.58  5.59 5.07-6.11  
Medicare 18.32 16.44-20.20  16.94 16.09-17.79  
Other Public 1.89 1.25-2.53  1.86 1.59-2.13  
Private  49.76 47.33-52.20  52.77 51.47-54.06  
CCI Score [mean (SE)] 0.82 (0.03)  0.51(0.01) <0.001* 
CCI Score (%)       <0.001* 
Zero Comorbidity 63.52 61.39-65.66  72.02 71.25-72.79  
One Comorbidity 23.93 22.08-25.78  20.18 19.67-20.78  
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Table 4-1. (Continued). 
 
 Adults (unweighted n=47,388)a  
 Anxiety disorder(s)    (unweighted n=3,610)a  
No anxiety disorder    
(unweighted n=43,778)  
Characteristics % 95% CI  % 95% CI p-value 
Two Comorbidity 8.74 7.56-9.92  5.63 5.29-5.97  
Three or More  3.81 3.02-4.60  2.17 1.95-2.39  
 
Notes: Unweighted numbers represent number of individuals in the sample, while weighted numbers represent projected 
number of individuals (i.e. national-level estimates), after controlling for the complex survey design of MEPS. CI = 
Confidence Interval; GED = Graduation Equivalency Degree; MSA = Metropolitan Statistical Area; CCI = Charlson 
Comorbidity Index; SE = Standard Error.  
a Sample estimates projected to 232,782,004 adults, among which 20,337,553 were classified as anxiety patients and the 
remaining 212,444,451 were considered as anxiety-free population. b Previously married refers to divorced, separated or 
widowed individuals. c Dual eligible refers to individuals who are entitled to Medicare Part A and/or Part B and also meet the 
eligibility requirements for Medicaid, therefore are enrolled in both programs. 
* p < 0.05, two-tailed.
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Table 4-2. Comparison of CCI clinical conditions between anxiety and non-anxiety patients. 
 
   Adults (unweighted n=47,388)a   
 
 Anxiety disorder(s) 
(unweighted n=3,610)a  
No anxiety disorder 
(unweighted n=43,778)a 
 
 
Comorbidities  % 95% CI  % 95% CI  p-value 
Myocardial infarction  3.31 2.51-4.10  2.92 2.65-3.18  0.318 
Congestive heart failure  1.49 1.02-1.96  0.94 0.79-1.09  0.004* 
Peripheral vascular disease  1.96 1.34.2.57  1.28 1.12-1.44  0.020* 
Dementia  0.95 0.51-1.40  0.53 0.40-0.66  0.034* 
Cerebrovascular disease  0.28 0.02-0.55  0.18 0.11-0.25  0.381 
Chronic Pulmonary disease  16.02 14.30-17.74  8.55 8.08-9.01  <0.001* 
Connective tissue disease  5.19 4.30-6.07  2.93 2.65-3.21  <0.001* 
Ulcer disease  0.91 0.55-1.26  0.43 0.32-0.54  0.002* 
Mild liver disease  0.74 0.41-1.07  0.48 0.38-0.57  0.058 
Hemiplegia  3.04 2.29-3.79  2.18 1.94-2.41  0.009* 
Moderate or severe renal disease  0.59 0.27-0.90  0.39 0.28-0.48  0.163 
Diabetes  12.24 10.93-13.54  10.78 10.28-11.28  0.032* 
Any tumor  7.06 5.87-8.26  6.10 5.69-6.52  0.110 
Leukemia  0.11 0.00-0.25  0.15 0.09-0.21  0.621 
Lymphoma  0.19 0.02-0.36  0.25 0.18-0.33  0.532 
Moderate or severe liver disease  0.26 0.06-0.46  0.30 0.21-0.38  0.759 
Metastasis solid tumor  0.65 0.34-0.97  0.45 0.36-0.54  0.168 
 
a Sample estimates projected to 232,782,004 adults, among which 20,337,553 were classified as anxiety patients and the 
remaining 212,444,451 were considered as anxiety-free population.  
* p < 0.05, two-tailed. 
Source: D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with 
administrative data bases. J Clin Epidemiol. Dec 1996;49(12):1429-1433.  
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2.93%; p < 0.001), ulcer disease (0.91% versus 0.43%; p = 0.002), hemiplegia (3.04% 
versus 2.18%; p = 0.009), and diabetes (12.24% versus 10.78%; p = 0.032). 
 
 
Direct Medical Costs Attributable to Anxiety Disorders 
 
 
Preliminary Statistical Analyses 
 
 As it was mentioned in chapter 3, direct medical costs associated with anxiety 
disorders were estimated using the incremental cost approach. In this regard, several 
multivariate regression analysis were conducted to separately model overall healthcare 
expenditure, inpatient visits expenditure, outpatient visits expenditure, emergency room 
visits expenditure, prescription medications expenditure, office-based medical visits 
expenditure, and other medical expenses. However, we first needed to find the set of 
covariates for regression models, as well as the type of regression analyses used to model 
healthcare cost data. As such, the following preliminary analyses were conducted.  
 
 Checking for multicollinearity. As it was mentioned in chapter 3, an initial set 
of variables, based on the relevant literature and availability of data in MEPS, was 
selected to be included in all regression analyses. However, in the presence of strong 
multicollinearity between two or more covariates of a model, predictions may be biased. 
In such cases, either some covariates should be excluded from the model, or those with 
high collinearity should be combined into a new single index Variance Inflation Factor 
(VIF) is highly being used by researchers to identify multicollinearity. VIF simply 
measures how much a variable is contributing to the standard error in the regression. If 
there is severe multicollinearity between two or more variables in a model, the variance 
inflation factor will be very large for those variables. The general rule of thumb to 
identify multicollinearity is to use the cut point of 10 for VIF.78 That is, if the VIF for a 
particular variable is higher than 10, that variable should either be excluded from the 
model or be combined with other variables with high VIFs. Some researchers though find 
the cut point of 10 to be very conservative and instead go with lower cut points such as 3 
or 4.78 The VIF cut point of 4 was selected in this study. 
 
 In order to find out if there is multicollinearity in our data, we run an OLS 
regression and asked for the VIF to be displayed in the output. The results are shown in 
Table 4-3. According to Table 4-3, the mean VIF for the set of covariates is equal to 
2.03. Also; the majority of independent variables have VIFs less than 4. The only 
variables with high VIFs are age 65 to 85 (VIF=7.48), and Medicare (VIF=5.71). It 
means that there is possibly a high collinearity between these two variables (people 65 
years and older are more likely to be enrolled in Medicare). However, we still can’t say 
that there is a severe collinearity between these two variables, since neither of the VIFs 
exceeds 10. Also, we cannot eliminate any of these two variables since they are all 
specific levels of other categorical variables (age and insurance). Finally, insurance 
coverage and age are shown to have significant impact on healthcare cost.79-83 Taking all 
these into account and after consulting with the biostatistician expert of the project, 
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Table 4-3. Results of regression analysis to check for multicollinearity. 
 
Variable VIF  Variable VIF 
No anxiety disordera    Poora   
Anxiety disorders 1.06  Low income 1.70 
Malea    Middle Income 2.39 
Female 1.05  High income 2.87 
Age 18 to 24a    Uninsureda   
Age 25 to 44 3.09  Dual eligible 1.72 
Age 45 to 64 3.67  Medicaid 1.34 
Age 65 and more 7.48  Medicare 5.71 
Whitea    Other public insurances 1.08 
Black 1.32  Private insurance only 2.01 
Hispanic 1.57  Northeasta   
Other 1.18  Midwest 1.88 
Marrieda    South 2.23 
Previously married 1.27  West 2.08 
Never married 1.73  Non MSAa  
No Degreea    MSA 1.09 
GED/high school diploma 1.90  Excellent PHSa  
Bachelor 1.87  Very good PHS 1.63 
Master/PhD 1.53  Good PHS 1.72 
Other degree 1.37  Fair PHS 1.56 
Poora    Poor PHS 1.30 
Near poor 1.27  Charlson Comprbidity Index 1.34 
 
Note: Mean VIF = 2.03. 
a Reference Category. 
VIF = Variance Inflation Factor. 
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we decided to keep all covariates in the model. 
 
 Finding the distribution of cost data. In modeling healthcare cost data, the 
specific distributional characteristics of the data must be taken into consideration. These 
characteristics are: (1) non-negative observations; (2) excessive zero (i.e. there are a large 
number of individuals with zero cost); and (3) highly skewed data (i.e. the majority of 
cost is incurred by a few patients).68 These characteristics make traditional Ordinary 
Least Square (OLS) regression inefficient in modeling healthcare cost data. Figure 4-1 
shows the distribution of overall healthcare cost for the study population. As it was 
expected, healthcare cost data is highly skewed. So, OLS regression could not be used to 
model this type of data. 
 
 Alternatively, OLS with natural log-transformed cost data has been widely used to 
deal with heavily skewed data. However, this approach has some limitations as well.68 
First, the outcome variable is the logarithm of cost. So in order to draw useful 
conclusions about the cost, the predicted values need to be retransformed back to the 
original scale. While retransforming the outcome variable, by using smearing factor, 
seems straightforward, interpretation of parameter estimates may still be challenging. 
Second, in the presence of heteroskedasticity, using one smearing factor to retransform 
the predicted values leads to biased estimates, i.e. under-estimation or over-estimation of 
the actual cost. Figure 4-2 depicts the distribution of the log-transformed overall cost for 
the study population. As it is shown in this figure, log-normal distribution is a perfect fit 
to our data and therefore, OLS with log-transformed cost data seems to be an appropriate 
regression model. However, we still needed to check for heteroskedasticity in log-
transformed data. Table 4-4 shows the result of Breusch-Pagan / Cook-Weisberg test for 
heteroskedasticity. According to this result, error terms have non-constants standard 
deviation. In other forms, heteroskedasticity is present with log-transformed data. So, 
OLS regression with log-transformed cost data was also ruled out. 
 
 In such scenarios, a Generalized Linear Model (GLM), with appropriate variance 
and link functions, is more efficient to model cost data. GLM directly models both the 
variance and mean functions on the original scale of dependent variable. As such, results 
can be interpreted with no need for retransformation from log scale to the original scale.68 
The link function generally used with healthcare cost data is the log-link function.68  
 
 In order to identify the appropriate variance function, a Park test was conducted. 
Result of this test, which is shown in Table 4-5, suggested that both Poisson and Gamma 
variance function might be appropriate for our data. We modeled overall healthcare cost 
data once using log-link GLM with Poisson distribution and then with log-link GLM with 
Gamma distribution These two models were compared based on (1) correlation between 
the predicted and observed expenditures (to see how well predictions of each model 
matched the observed data), and (2) mean squared error (as a summary of overall 
goodness of fit for each model). The comparison is shown in Table 4-6. Finally, a log-
link GLM with Poisson distribution was selected as the best fitting model for modeling 
the overall healthcare expenditure, as well as all categories of expenditure. 
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Figure 4-1. Distribution of the overall healthcare cost for the study population. 
 
Mu = Mean, Sigma = Standard Deviation. 
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Figure 4-2. Distribution of the log-transformed overall healthcare cost for the 
study population. 
 
Mu= Mean, Sigma=Standard Deviation, totlog=log-transformed overall cost. 
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Table 4-4. Results of the Breusch-Pagan/Cook-Weisberg test for 
heteroskedasticity.  
 
Variable Chi-square P-value 
totlog 360.07 < 0.0001* 
 
Note: The null hypothesis in the Breusch-Pagan / Cook-Weisberg test is that all error 
terms have constant variance. Since the P-value is less than 0.05, we reject the null 
hypothesis. In other words, heteroskedasticity is present. 
totlog =  log-transformed overall cost. 
 
 
 
Table 4-5. Results of Park test. 
 
Parameter estimate (λ) SE 95% CI p-value 
1.64 0.01 1.61-1.66 < 0.0001* 
 
Note: Since the parameter estimate for the λ is between 1 and 2, it means that both 
Poisson variance function (λ=1), and Gamma variance function (λ=2) could be 
appropriate candidates. 
SE = Standard Error, CI = Confidence interval. 
* p < 0.05, two-tailed. 
 
 
 
Table 4-6. Comparison of Poisson and Gamma variance functions. 
 
Variance 
function 
Correlation between predicted 
and observed values 
Mean square error 
(MSE) 
Poisson 0.39 1.19e+08 
Gamma 0.34 2.07e+08 
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 After deciding on the best fitting regression model, several multivariate regression 
analyses were conducted to separately model overall healthcare expenditure, inpatient 
visits expenditure, outpatient visits expenditure, emergency room visits expenditure, 
prescription medications expenditure, office-based medical visits expenditure, and other 
medical expenses. Results are provided in the following sections. 
 
 
Overall Incremental Direct Medical Expenditure Attributable to Anxiety Disorders 
 
 Table 4-7 shows the result of regression analysis to estimate the overall 
incremental direct medical expenditure attributable to anxiety disorders. After controlling 
for gender, age, race/ethnicity, marital status, education, poverty category, geographic 
region, MSA, PHS, health insurance coverage, and the CCI, adults with anxiety disorders 
had 33% higher overall medical expenditure than those without anxiety disorders 
(parameter estimate: 1.33; p < 0.001). The adjusted annual overall incremental medical 
expenditure associated with anxiety disorders was estimated at $1657.52 per person (SE: 
$238.83; p < 0.001).The total annual incremental direct medical expenditures attributable 
to anxiety disorders, for the U.S. ambulatory adult population, is at $33.71 billion in 2013 
US dollars. This figure was obtained by multiplying the per-capita incremental cost of 
anxiety ($1657.52) by the national estimated prevalence of anxiety disorders in MEPS 
(20.34 million persons). 
 
 
Incremental Direct Medical Expenditure by Health Delivery Setting (SA2) 
 
 Results from individual regression models of the incremental expenditure 
attributable to anxiety disorders, by service category, are described in Table 4-8. The 
adjusted annual incremental medical expenditure associated with anxiety disorders by 
health service category are as follow: Inpatient care, estimated at $567.83 (SE: 176.65, p 
= 0.001) accounted for the largest proportion of the overall medical expenditures. 
Prescription medications at $531.83 (SE: 64.34; p < 0.001) accounted for the second 
largest proportion of the overall expenditures, followed by office-based medical provider 
visits at $362.41(SE: 79.58, p < 0.001). Although statistically significant, emergency 
room visits and other medical expenses together explained less than 8% of the overall 
medical expenditure. These cost categories were estimated at $37.02 (SE: 18.28; p = 
0.043) and $80.85 (SE: 38.87, p = 0.038), respectively. Cost of outpatient visits estimated 
at $42.52 (SE: 54.69; p = 0.437), was not statistically significant. 
 
 
Incremental Direct Medical Expenditure for Different Sub-populations (SA3) 
 
 In order to estimate the incremental direct medical expenditures associated with 
anxiety disorders for different sub-populations (based on gender, age, race/ethnicity, 
marital status, education, poverty category, region, MSA, and insurance coverage), 
separate multivariate regression analyses (GLM with Poisson distribution and log-link 
function) were conducted. To estimate the costs in each sub-population, the regression  
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Table 4-7. Results of regression analysis to estimate the overall incremental 
direct medical expenditure associated with anxiety disorders. 
 
Parameter  Parameter estimate  SE  95% CI  p-value 
No anxiety disorderb         
Anxiety disorders  1.33  0.05  1.24-1.43  < 0.001 
Maleb         
Female  1.17  0.03  1.11-1.24  < 0.001 
Age 18 to 24b         
Age 25 to 44  1.08  0.06  0.97-1.21  0.174 
Age 45 to 64  1.51  0.09  1.34-1.71  < 0.001 
Age 65 and Older  1.33  0.11  1.13-1.57  0.001 
Whiteb         
Black  0.94  0.04  0.88-1.02  0.113 
Hispanic  0.74  0.03  0.68-.80  < 0.001 
Other  0.71  0.04  0.64-0.78  < 0.001 
Marriedb         
Previously 
marriedc  0.99  0.03  0.93-1.06  0.873 
Never married  0.91  0.04  0.84-0.98  0.016 
No Degreeb         
GED/high school 
diploma  1.17  0.05  1.07-1.27  0.001 
Bachelor  1.39  0.08  1.25-1.55  < 0.001 
Master/PhD  1.42  0.09  1.26-1.61  < 0.001 
Other degree  1.25  0.08  1.11-1.41  < 0.001 
Poorb         
Near poor  0.93  0.05  0.83-1.05  0.238 
Low income  1.02  0.05  0.93-1.12  0.689 
Middle Income  1.02  0.05  0.93-1.12  0.687 
High income  1.16  0.06  1.04-1.30  0.006 
Uninsuredb         
Dual eligibled  3.63  0.35  3.00-4.40  < 0.001 
Medicaid  2.28  0.17  1.97-2.63  < 0.001 
Medicare  2.92  0.23  2.50-3.41  < 0.001 
Other public   2.10  0.18  1.77-2.50  < 0.001 
Private  1.93  0.12  1.71-2.17  < 0.001 
Northeastb         
Midwest  1.04  0.05  0.96-1.14  0.345 
South  0.94  0.04  0.86-1.02  0.136 
West  0.99  0.04  0.91-1.08  0.759 
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Table 4-7. (Continued). 
 
Parameter  Parameter estimate  SE  95% CI  p-value 
Non MSAb         
MSA  1.14  0.04  1.06-1.23  0.001 
Excellent PHSb         
Very good PHS  1.36  0.06  1.25-1.49  < 0.001 
Good PHS  2.02  0.09  1.86-2.20  < 0.001 
Fair PHS  3.12  0.18  2.78-3.51  < 0.001 
Poor PHS  4.50  0.32  3.91-5.18  < 0.001 
CCI  1.19  0.01  1.17-1.21  < 0.001 
Intercept  627.05  63.76  513.14-766.24  < 0.001 
 
Notes: Results are based on generalized linear model with log-link function and Poisson 
distribution. Unweighted number of individuals = 46,572. 
SE = Standard Error; CI = Confidence Interval; GED= Graduation Equivalency Degree; 
MSA = Metropolitan Statistical Area; PHS= Perceived Health Status; CCI = Charlson 
Comorbidity Index. 
a Sample estimates projected to 228,987,954 adults with positive person weights and non-
missing values on all of the independent variables; b Reference Category; c Previously 
married refers to divorced, widowed, or separated individuals; d Dual eligible refers to 
individuals who are entitled to Medicare Part A and/or Part B and also meet the eligibility 
requirements for Medicaid, therefore are enrolled in both programs. 
 
 
 
Table 4-8. Results of regression analyses to estimate the incremental 
expenditures of anxiety disorders by service category. 
 
Service category AIC ($) SE p-value Total costa %b 
Inpatient visits 567.83 176.65 0.001 $11.55 B 35.00% 
Outpatient visits 42.52 54.69 0.437 $864.75 M 2.62% 
Office-based visits 362.41 79.58 <0.001 $7.37 B 22.34% 
Emergency room visits 37.02 18.28 0.043 $752.90 M 2.28% 
Prescription medications 531.83 64.34 <0.001 $10.82 B 32.78% 
Other medical expenses 80.85 38.87 0.038 $1.64 M 4.98% 
Overall expenditure 1657.52 238.83 <0.001 $33.71 B 100.00% 
 
Note: All costs are presented in 2013 US dollars. 
AIC = Average Incremental Cost; SE = Standard Error; B = Billion; M = Million. 
a Calculated by multiplying the average incremental cost by the prevalence of anxiety 
disorders in MEPS (i.e. 20.34 million persons). b Percent of overall expenditure. 
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analysis was conducted on that sub-population only and therefore, the covariate 
identifying that sub-population was excluded from the regression model. For instance, to 
estimate the incremental cost of anxiety disorders among males, the regression analysis 
was conducted on males, excluding gender from covariates of the model. Results are 
provided in Table 4-9. 
 
 According to these findings, having anxiety disorder(s) leads to statistically 
significant increase in direct medical expenditures almost for all sub-populations. The 
only exceptions are Hispanics, individuals with education levels lower than GED, and 
those who are uninsured, have Medicaid, or other public insurances (such as VA, 
Tricare,…). The highest increases in direct medical costs as a result of anxiety disorder(s) 
were seen in the following sub-populations: dual-eligible, those who live in non-MSA 
regions, highly educated individuals (with Master or PhD degree), seniors (65 years of 
age and older), Medicare enrollees, Midwest residents, divorced, widowed, or separated 
individuals, females, people with middle income, and Whites (non-Hispanic).  
 
 We have looked at the cost of anxiety disorders among Blacks and Whites (but 
not Hispanics, since presence of anxiety disorders did not have a statistically significant 
impact on healthcare cost of this population) even further. More specifically, we broke 
down each of these race/ethnicity categories, by age, gender and geographic region. The 
totals of 24 separate multivariate regression analyses were conducted to estimate cost of 
anxiety disorders in each of these groups. Results are provided in Table 4-10. According 
to these results, for both race/ethnicity groups (White non-Hispanics and Black non-
Hispanics) females and individuals 45 years and older accounted for the majority of cost. 
This is the exact same observation we had when looking at the costs of all race/ethnicities 
together.  
 
 Regarding geographic region, we found that geographic variations did not impact 
cost of anxiety disorders among White non-Hispanics. In fact, in all geographic regions, 
anxiety disorders led to statistically significance increase in direct medical expenditures 
among White non-Hispanics. More specifically, White non-Hispanics who reside in 
Midwest had higher costs (similar to what we had already found for all race/ethnicities 
combined). However, Blacks had different cost pattern. In fact, among Black non-
Hispanics, only those who reside in northeast had higher medical costs due to anxiety 
disorders and for other geographic regions, anxiety related costs were not statistically 
significant. It should be further investigated to see whether prevalence of anxiety 
disorders is higher among Blacks in northeast, or the zero cost of anxiety disorders for 
people of color, who reside in other regions, is due to some barrier in receiving the 
required care.  
 
 These findings all demonstrate why it is important to calculate values for 
subgroups. If we just looked at the incremental costs for men among Whites and Blacks, 
it looks like the costs are very similar ($1213.60 and. $1216.57) (Table 4-10). However, 
looking at the age segments, we saw that the costs for White non-Hispanic males were 
similar between age groups ($1172.83 and $1116.29), but they were incredibly different 
for Black non-Hispanic males, where older Black males had an incremental cost nearly  
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Table 4-9. Incremental direct medical expenditures associated with anxiety 
disorders for different sub-populations. 
 
Sub-population Adjusted mean incremental cost ($) SE p-value 
Gender 
Male 963.97 342.64 0.005* 
Female 2137.98 330.96 < 0.001* 
Age in years 
18-24 1498.39 439.97 0.001* 
25-44 771.47 281.03 0.006* 
45-64 2102.74 432.29 < 0.001* 
65 and more 2426.40 765.072 0.002* 
Race/ethnicity 
White non-Hispanic 1879.31 310.15 < 0.001* 
Black non-Hispanic 1459.30 671.15 0.030* 
Hispanic 472.98 344.68 0.170 
Marital Status 
Married 1522.56 370.62 < 0.001* 
Previously Marrieda 2305.23 588.36 < 0.001* 
Never Married 1814.21 393.55 < 0.001* 
Education    
None 1069.70 560.54 0.056 
GED/High School 
Diploma 1795.34 324.47 < 0.001
* 
Bachelor 1615.17 552.84 0.003* 
Master/PHD 2463.31 1058.67 0.020* 
Poverty Category    
Poor 1710.80 555.70 0.002* 
Near Poor 1594.02 1089.02 0.143 
Low Income 1087.15 601.07 0.070 
Middle Income 2048.08 423.33 < 0.001* 
High Income 1469.45 473.18 0.002* 
Region    
Northeast 1463.21 495.22 0.003* 
Midwest 2338.59 572.02 < 0.001* 
South 1197.91 364.88 0.001* 
West 1718.05 421.48 < 0.001* 
MSA    
Non-MSA 2485.64 621.19 < 0.001* 
Insurance Coverage    
Uninsured 483.63 313.77 0.123 
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Table 4-9. (Continued). 
 
 
Note: All costs are presented in 2013 US dollars. 
a Previously married refers to divorced, widowed, or separated individuals. b Dual eligible 
refers to individuals who are entitled to Medicare Part A and/or Part B and also meet the 
eligibility requirements for Medicaid, therefore are enrolled in both programs. 
SE = Standard Error; GED= Graduation Equivalency Degree; MSA = Metropolitan 
Statistical Area. 
* p < 0.05, two-tailed 
 
 
 
  
Sub-population Adjusted mean incremental cost ($) SE p-value 
Dual Eligibleb 6455.84 1990.81 0.001* 
Medicaid 1129.83 769.44 0.142 
Medicare 2354.90 778.10 0.002* 
Other Public 781.37 891.45 0.381 
Private Only 1571.62 319.97 < 0.001* 
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Table 4-10. Breaking down the cost of anxiety disorders among different 
race/ethnicities by gender, age, and geographic region. 
 
 Incremental direct medial cost (SE) 
Sub-population White non-Hispanic Black non-Hispanic 
Gender    
Male  1213.60 (475.32)* 1216.57 (920.13) 
Female  2318.78 (424.48)* 1797.20 (865.29)* 
Agea    
18-44  1060.49 (307.34)* 1268.23 (803.82) 
45 and over  2431.47 (497.92) * 2189.18 (995.05) * 
Region    
Northeast  1406.38. (532.84) * 3899.40 (1890.84) * 
Midwest  2071.76 (600.52) * 824.05 (1054.74)  
South  1413.00 (435.31) * 491.19 (645.86) 
West  1478.93 (450.03) * 2001.25 (1459.93) 
Gender - Age    
Male - 18 to 44 
Male - 45 and over 
 1172.83 (444.11) * 650.61 (417.22)  
 1116.29 (738.16) 3932.22 (1767.89) * 
Female - 18 to 44 
Female - 45 and over 
 1235.21 (456.88) * 2315.74 (1277.64) 
 3150.09 (696.68) * 1843.72 (1314.72) 
 
Note: All costs are presented in 2013 U.S. dollars; Results are not provided for the 
Hispanics, since presence of anxiety disorder(s) did not have a statistically significant 
impact on healthcare cost of this population. 
a Age groups were combined to get enough sample size in each cell. 
SE = Standard Error. 
* p < 0.05, two-tailed. 
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six times that of the 18-44 year old ($3932.22 and $650.61). For women, we saw a 
difference in the costs by age group, but older White women had a higher cost (nearly as 
much as older Black men) and for Black women we saw higher cost is in the younger age 
group. So, there is a need for future studies to figure out why all of these incremental 
costs vary so much. 
 
 
Morbidity Cost Associated with Anxiety Disorders 
 
 As it was mentioned in the third chapter, morbidity cost was measured using the 
Human Capital Approach (HCA). In the HCA, productivity loss due to an illness or 
injury is approximated by valuing the entire period of absence from work by average 
individual’s earning. For individuals who are at paid employment for at least one round 
in the year, information on wage rates are available in the MEPS (in both Consolidated 
Data file and Job file). For unemployed individuals, the period in which they had to stay 
in bed due to an illness or injury is valued by the average wage for private household 
services. Equation 4-1 shows the formula to calculate the morbidity cost. 
 
Morbidity Cost ? ?? ????? ??????
?
???
? ???????
? ? ???? (Eq. 4-1) 
 
Where: 
N = Total number of individuals in the sample. 
Wti = Person weight for the ith individual in the sample. 
Wgi = Daily wage for employed individuals and average daily wage for household 
services if the individual is not employed. 
ni = Number of missed work days (due to anxiety disorders) for employed individuals and 
number of days stayed in bed (due to anxiety disorders) for unemployed individuals. 
Nanx = Weighted number of individuals in the sample with anxiety disorder(s). 
 
 
Number of Missed Work Days due to Anxiety Disorders for Employed Individuals 
 
 Since MEPS reports the total number of missed work days for each individual 
(due to all medical conditions he/she might have), we needed to find the incremental 
number of missed work days specifically due to anxiety disorders. A multivariate 
regression analysis was conducted (the very same approach we used to estimate the 
incremental direct medical costs). The outcome variable was the total number of missed 
work days and the covariates were gender, age, race/ethnicity, marital status, education, 
geographic region, MSA, Charlson comorbidity index, occupation category, union status, 
number of employees, and sick pay (whether or not the person has the sick pay benefit).  
 
 Checking for multicollinearity. Table 4-11 shows the results of 
multicollinearity analysis. VIF for insurance coverage and poverty category were 
estimated at 5.78 and 4.91 respectively. Since both of these values exceeded the cut point 
of 4, and also there is no evidence in the literature supporting the impact of these  
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Table 4-11. Results of multicollinearity analysis for modeling the number of missed work days. 
 
Variable VIF  Variable VIF 
No anxiety disordera    Management, business, and financial operationsa  
Anxiety disorders 1.03  Professional and related occupations 2.31 
Malea    Service Occupations 2.37 
Female 1.22  Sales and related occupations 1.75 
Age 18 to 24a    Office and administrative support 2.11 
Age 25 to 44 3.53  Farming, fishing, forestry 1.14 
Age 45 to 64 3.97  Construction. Extraction, and maintenance 1.64 
Age 65 to 85 1.44  Production, transportation 2.06 
Whitea    Sick-pay benefita  
Black 1.24  No sick-pay benefit 1.34 
Hispanic 1.30  Uniona  
Other 1.12  Non-union 1.13 
Marrieda    Number of employees 1.11 
Previously married 1.19  Northeasta   
Never married 1.46  Midwest 2.10 
No Degreea    South 2.35 
GED/high school diploma 3.08  West 2.14 
Bachelor 3.03  Non MSAa   
Master/PhD 2.35  MSA 1.06 
Other degree 1.95  Charlson Comprbidity Index 1.08 
 
Note: Mean VIF = 1.85. 
a Reference Category. 
VIF = Variance Inflation Factor. 
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variables on the number of missed work days,72 they were excluded from the model. 
There is no multicollinearity with the remaining set of covariates.  
 
 Finding the distribution of missed work days. Figure 4-3 shows the 
distribution of number of missed work days (“wkinbd” variable in the MEPS data file). 
Since the “wkinbd” had a highly-skewed distribution, use of OLS regression would have 
led to biased estimates. So, OLS with log-transformed data and GLM regression were 
considered. OLS with log-transformed data was ruled out; due to the heteroskedasticity in 
data (result of the test for heteroskedasticity is provided in Table 4-12). Therefore, we 
conducted the park test to identify the best variance function to be used in the GLM 
regression (Table 4-13). 
 
 According to the results of Park test, both Poisson and Gamma variance functions 
were appropriate fit to our data. We conducted a. log-link GLM with Poisson distribution 
(to be consistent with the methodology used in estimating the direct medical costs), on 
the employed individuals 18 years and older. Self-employed individuals were not 
included in the analysis since information such as sick leave is not provided for them in 
the MEPS. Table 4-14 shows the result of regression analysis to estimate the incremental 
number of days missed work due to anxiety disorders. Based on these results, having 
anxiety disorder(s) has increased the number of missed work days by almost 2.5 days.  
 
 
Number of Days Stayed in Bed due to Anxiety Disorders for Unemployed 
Individuals 
 
 For unemployed individuals, MEPS collects the total number of days each 
individual had to stay in bed (due to all medical conditions he/she might have had during 
the survey year). The variable representing this information in the MEPS consolidated 
data file is called “ddbdys”.we needed to find the incremental number of bed days 
specifically due to anxiety disorders. Distributional characteristics of the variable 
“ddbdys” were pretty the same as they were for the variable “wkinbd”. In other words, 
“ddbdys” was also highly skewed and error terms from the OLS regression on log-
transformed “ddbdys” were also heteroskedastic. So, we conducted a log-link GLM with 
Poisson distribution on the unemployed individuals in the sample to estimate the 
incremental number of bed days due to anxiety disorder (s). The dependent variable in 
the regression model was “ddbdys” and independent variables were gender, age, 
race/ethnicity, education, marital status, geographic region, MSA, and Charlson 
comorbidity index. Poverty category and insurance coverage were excluded from the set 
of covariates due to their high multicollinearity with other variables (high VIF).       
Table 4-15 shows the result of regression analysis to estimate number of bed days due to 
anxiety disorders for unemployed individuals. As one can see, having anxiety disorders 
has increased the number of bed days by more than 12 days, for unemployed individuals. 
  
 62 
 
 
 
Figure 4-3. Distribution of the number of missed work days for employed 
individuals. 
 
WKINBD = Number of missed work days. 
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Table 4-12. Results of the Breusch-Pagan/Cook-Weisberg test for 
heteroskedasticity.  
 
Variable Chi-square p-value 
wkinbd_log 218.33 < 0.0001* 
 
Note: The null hypothesis in the Breusch-Pagan / Cook-Weisberg test is that all error 
terms have constant variance. Since the P-value is less than 0.05, we reject the null 
hypothesis. In other words, heteroskedasticity is present. 
wkinbd_log = log-transformed missed work days. 
 
 
 
Table 4-13. Results of Park test. 
 
Parameter estimate (λ) SE 95% CI p-value 
1.90 0.04 182-1.98 < 0.0001* 
 
Note: Since the parameter estimate for the λ is between 1 and 2, it means that both 
Poisson variance function (λ=1), and Gamma variance function (λ=2) could be 
appropriate candidates. 
SE = Standard Error, CI = Confidence interval. 
* p < 0.05, two-tailed. 
 
 
 
Table 4-14. Incremental number of missed work days due to anxiety disorders. 
 
Incremental estimate SE 95% CI p-value 
2.18 0.57 1.05,3.30 < 0.0001* 
 
SE = Standard Error, CI = Confidence interval. 
* p < 0.05, two-tailed. 
 
 
 
Table 4-15. Incremental number of bed days due to anxiety disorders. 
 
Incremental estimate SE 95% CI p-value 
12.55 1.62 9.38,15.72 < 0.0001* 
 
SE = Standard Error, CI = Confidence Interval. 
* p < 0.05, two-tailed. 
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Daily Wage for Employed Individuals 
 
 For individuals who were employed for at least one round during the survey year, 
MEPS collects information on hourly wages, as well as the number of hours a person 
works during a week. To convert hourly wages to daily wages, we assumed that each 
individual worked 5 days a week. So, daily wage for employed individuals was 
calculated according to the Equation 4-2. 
 
DW= hours worked per day* HW = (hours worked per week/5) * HW (Eq. 4-2) 
 
Where: 
DW = Daily wage. 
HW = Hourly wage as it comes in the MEPS consolidated data file. 
 
 
Average Daily Wage of Household Services for Unemployed Individuals 
 
 As it was mentioned in the chapter 3, in the HCA, morbidity cost for unemployed 
individuals is calculated by valuing the time period in which an individual had to stay in 
bed, due to an illness or injury (bed days).the assumption is that daily wage for 
unemployed individuals is equal to the daily wage for services usually being done at 
home (household services). For each survey year (2009 and 2010), we used the average 
daily wage for cooks, maids and maintenance services, as the average daily wage for 
household services. Results are provided in Table 4-16. 
 
 
Summary of Analyses 
 
 Having all the information required to calculate the morbidity cost attributed to 
anxiety disorders (according to Equation 4-1), summary of results are provided in Table 
4-17. The adjusted mean incremental morbidity cost due to anxiety disorders was 
estimated at $625.73 in 2013 US dollars. Multiplying this figure by the weighted number 
of individuals with anxiety disorder(s) in this period (i.e. 20,337,553 adults), the total 
morbidity cost associated with this category of mental illnesses was estimated at $12.72 
billion in 2013 US dollars. 
 
 
Mortality Costs Associated with Anxiety Disorders 
 
 As it was already defined in the chapter 3, mortality cost is productivity loss due 
to premature deaths. In the HCA, mortality cost is the present value of future earnings, 
from age of death to life expectancy. In this regard, mortality cost in HCA is calculated 
using the formula in Equation 4-3. 
 
??? ? ? ????????????
?????????
??
??
????
 (Eq. 4-3) 
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Table 4-16. Average daily wage for unemployed individuals based on BLS data. 
 
  Weekly wage ($)a  Daily wage ($)b 
Gender  Service category 2009 2010  2009 2010 
Men  Cook 400 401  
   Maid 444 455  
 Maintenance 488 493  
  Average 444 450  97 96 
Women  Cook 371 381  
   Maid 371 376  
 Maintenance 388 391  
  Average 377 383  82 82 
 
Note: Wage data for specific service categories is not available by further details such as 
race/ethnicity. 
a In the current dollar value; b In 2013 dollar value. 
 
 
 
Table 4-17. Summary of results: Morbidity cost. 
 
Cost Adjusted incremental estimate ($) SE 95% CI p-value 
Average 625.73 7.40 611.14,640.32 < 0.0001* 
Total 625.37*20,337,553= $12.72 billion in 2013 US dollars 
 
SE = Standard Error, CI = Confidence interval. 
* p < 0.05, two-tailed. 
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Where:  
MTC = Mortality cost for individuals who committed suicide due to anxiety disorders in 
the period of study. 
Ad= Age of death. 
Le= Life expectancy at age of death by race/ethnicity and gender. 
Li= Labor force participation rate by gender and race/ethnicity at age i. 
W= Average annual wage by gender and race/ethnicity at age of death. 
Discount rate is equal to 3%. 
 
 
Number of People Who Committed Suicide due to Anxiety Disorders and Age at 
Death 
 
 NVSS provides number of deaths by age group, gender, Hispanic origin, and race 
for non-Hispanic origin for different causes of death. These statistics are reported in 
several different formats, based on the age group (5-year age group or 10-year age group) 
and causes of death (for 15 major causes of death or for 113 causes of death).56-58 We 
started collecting the number of deaths due to suicides for 2010, using the number of 
deaths provided by 15 major causes of death in 5-year age groups, by Hispanic origin, 
race for non-Hispanic population and sex. However, if for some specific sub-populations 
suicide did not appeared in the first 15 causes of death, we had to use other data tables to 
collect as much information as possible. Number of deaths due to suicide by age, gender, 
and race/ethnicity are provided in Table 4-18. You may see that for some sub-
populations the number of suicides is provided for 5-year age groups and for others in 10-
year age group. Since we had the number of deaths for each age group but not at each 
specific age, we assumed that all deaths in each age group (either 5 or 10 year age 
groups) have occurred in the middle point of that range. For instance, we assumed that 
for all deaths between the ages of 20 to 25, the age at death was 22. In the same way, we 
assumed that for all deaths occurred between the ages 65 to 75, the age at death was 70.  
 
 It has been shown that 10% of suicides are due to anxiety disorders.5,10 So, to get 
the number of suicide due to anxiety disorders at certain age by gender and race/ethnicity, 
we multiplied the figures in Table 4-18 by 10%.  
 
 
Life Expectancy at Age of Death by Race/Ethnicity and Gender 
 
 NVSS also provides statistics on life expectancy at age of death by race/ethnicity 
and gender.59 This information is provided in Table 4-19. If the age at death was a 
multiplication of 10 (for 10-year age group), then we already have the life expectancy at 
that age. However, for 5-year age groups (for instance 20 to 25), the life expectancy at 
the age of death (22) is equal to the mean of life expectancies at the beginning (20) and 
end (25) of that range. 
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Table 4-18. Number of suicides in 2010 by age, gender, and race/ethnicity. 
 
Age 
group 
  White  Black  Hispanic 
  Male  Female  Male  Female  Male  Female 
 n %  n %  n %  n %  n %  n % 
20-24  1,717 84%  335 16%  259 84%  49 16%  307 82%  68 18% 
25-29  1,822 82%  410 18%  239 85%  43 15%  272 84%  51 16% 
30-34  1,658 79%  445 21%  186 88%  26 12%  232 88%  33 12% 
35-39  1,887 77%  567 23%  180 79%  47 21%  211 78%  59 22% 
40-44  2,213 76%  692 24%  160 77%  48 23%  196 83%  39 17% 
45-49  2,928 77%  878 23%  140 80%  36 20%  197 82%  42 18% 
50-54  2,996 76%  953 24%  119 76%  37 24%  150 82%  33 18% 
55-59  2,549 76%  821 24%  97 48%  
36 18% 
 138 83%  29 17% 
60-64  1,806 76%  558 24%  70 34%   67 78%  19 22% 
65-69  1,210 79%  322 21%  66 94%  4 6%  57 78%  16 
22% 
70-74  972 84%  179 16%    40 78%  11 22% 
75-79  878 47%  
246 13% 
 
38 79% 
 
10 21% 
 
59 89% 
 
7 11% 
80-84  761 40%      
85+  791 88%  110 12%  9 75%  3 25%  29 97%  1 3% 
Total   24,188 79%  6,516 21%  1,563 82%  339 18%  1,955 83%  408 17% 
 
Sources: Deaths, percent of total deaths, and death rates for the 15 leading causes of death in 10-year age groups, by Hispanic origin, 
race for non-Hispanic population and sex: United States, 2010. Mortality Tables 2012; 
http://www.cdc.gov/nchs/nvss/mortality_tables.htm. Accessed 11/25/2012 ; Deaths, percent of total deaths, and death rates for the 15 
leading causes of death in 5-year age groups, by Hispanic origin, race for non-Hispanic population and sex: United States, 2010. 
Mortality Tables 2012; http://www.cdc.gov/nchs/nvss/mortality_tables.htm. Accessed 11/25/2012; Deaths, percent of total deaths and 
rank order for 113 selected causes of death and Enterocolitis due to Clostridium difficile, by Hispanic origin, race for non-Hispanic 
origin and sex, United States, 2010, Mortality Tables 2012.
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Table 4-19. Life expectancy at selected ages by race, Hispanic origin, race for non-
Hispanic population, and sex: United States, 2010. 
 
  Hispanic  White non-Hispanic  
Black non-
Hispanic 
Age at 
death  Male Female  Male Female  Male Female 
20  59.3 64.4  57.2 61.1  52.9 58.8 
25  54.6 59.5  52.5 56.9  48.4 54.0 
30  49.8 54.6  47.9 52.0  43.9 49.2 
35  45.1 49.7  43.2 47.2  39.4 44.5 
40  40.4 44.8  38.6 42.5  34.9 39.8 
45  35.7 40.0  34.0 37.8  30.5 35.3 
50  31.2 35.3  29.7 33.2  26.3 31.0 
55  26.6 30.8  25.5 28.8  22.5 26.8 
60  22.8 26.3  21.5 24.4  19.0 22.9 
65  18.8 22.0  17.7 20.3  15.8 19.1 
70  15.1 18.0  14.2 16.4  12.8 15.7 
75  11.7 14.1  11.0 12.8  10.1 12.5 
80  8.7 10.7  8.1 9.6  7.8 9.6 
85  6.1 7.7  5.8 6.9  5.9 7.1 
90  4.2 5.4  4.0 4.8  4.4 5.2 
95  2.9 3.7  2.8 3.3  3.3 3.8 
100  2.1 2.6  2.1 2.3  2.6 2.8 
 
Source: Murphy SL, Xu JQ, Kochanek KD. Deaths: Final Data for 2010. National Vital 
Statistics Reports. Hyattsville, MD: National Center for Health Statistics;2013. 
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Labor Force Participation Rate and Wage 
 
 We collected information on LFPR and wage from the BLS.52,53 This information 
is provided in Tables 4-20 and 4-21 respectively. In BLS, wage data are available only 
for age groups of 16-24, 25-54, and 55+. So, we could not break down the wage data into 
finer age groups. 
 
 
Summary of Analyses 
 
 Having all the information required to calculate mortality cost according to 
Equation 4-3, results of this section are provided in Table 4-22. Assuming that 10% of 
suicides are due to anxiety disorders, 3,497 individuals committed suicide in 2010, with 
anxiety disorder(s) as primary reason. This resulted in $2.34 billion (in 2013 US dollars) 
loss in terms of mortality cost. White-non Hispanics accounted for almost 90% of this 
figure, mainly because of significantly higher number of suicides in this sub-population. 
Among White-non Hispanics, males between the ages of 25 and 44 years, had the highest 
mortality cost (37.71% of total mortality cost). 
 
 
The Societal Cost of Anxiety Disorders for the U.S. Adult Population in 2010 (SA1) 
 
 The societal cost of anxiety disorders was estimated, by adding-up the overall 
direct medical cost, morbidity cost, and mortality cost, at almost $49 billion in 2013 US 
dollars. Direct medical cost accounted for the majority of this figure (69.12%), followed 
by morbidity cost at 26.08% and mortality cost at 4.81%. These results are provided in 
Table 4-23. 
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Table 4-20. Labor force participation rate by age, gender, and race/ethnicity. 
 
  White non-Hispanic  Black non-Hispanic  Hispanic 
Age 
group  Men Women  Men Women  Men Women 
20-24  77.0 69.7  66.9 66.9  80.0 61.6 
25-29  90.0 76.2  82.3 76.7  91.9 67.7 
30-34  92.3 73.6  84.7 79.3  93.5 64.9 
35-39  93.3 73.7  86.8 78.2  94.1 66.7 
40-44  91.6 76.2  85.5 77.1  91.5 69.3 
45-49  89.7 77.2  79.6 75.3  88.6 72.2 
50-54  86.5 75.3  75.1 70.6  86.7 67.7 
55-59  79.7 69.4  65.2 63.6  77.1 60.5 
60-64  61.3 51.7  46.7 44.2  57.8 44.5 
65-69  37.2 27.6  27.9 24.2  38.7 24.3 
70-74  22.5 15.0  16.3 13.0  23.4 10.4 
75+  10.5 5.3  9.3 5.6  10.9 5.5 
 
Source: Labor Force Statistics from the Current Population Survey. Bureau of Labor 
Statistics. http://bls.gov/data/. Accessed 11/05/2012. 
 
 
 
Table 4-21. Median usual weekly earnings in current dollar from current 
population survey for 2010. 
 
  White non-Hispanic  Black non-Hispanic  Hispanic 
Age group  Men Women  Men Women  Men Women 
16-24  453 424  403 404  395 392 
25-54  878 715  656 615  587 529 
55+  990 734  740 614  617 521 
 
Notes: Wage data are in 2010 US dollars; in converting weekly wages to annual wages, 
the assumption was that each year is consisted of 52 weeks. 
Source: Weekly and Hourly Earnings from the Current Population Survey Bureau of 
Labor Statistics. http://bls.gov/data/. Accessed 11/05/2012 
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Table 4-22. Mortality cost: Summary of results. 
 
   White non-Hispanic  Black non-Hispanic  Hispanic 
Age 
group %/$
a Male Female Both sexes  Male Female Both sexes  Male Female Both sexes 
18-24 
$  247.09 M 32.23 M 279.33 M  24.46 M 3.99 M 28.45 M  29.62 M 4.36 M 33.98 M 
%  10.54 1.38 11.92  1.04 0.17 1.21  1.26 0.19 1.45 
25-44 
$  883.91 M 159.56 M 1.04 B  58.92 M 10.31 M 69.23 M  71.43 M 9.31 M 80.75 M 
%  37.71 6.81 44.52  2.51 0.44 2.95  3.05 0.40 3.45 
45-65 
$  591.12 M 114.36 M 705.48 M  14.25 M 3,06 M 17.31 M  21.1 M 2.90 M 23.99 M 
%  25.22 4.88 30.10  0.61 0.13 0.74  0.90 0.12 1.02 
65+ 
$  33.50 M 26.63 M 60.13 M  500,945 27,077 528,022  988,306 112,941 1.10 M 
%  1.43 1.14 2.57  0.02 0.00 0.02  0.04 0.00 0.05 
All 
Ages 
$  1.76 B 332.79 M 2.09 B  98.13 M 17.34 M 115.52 M  123.14 M 16.67 M 139.82 M 
%  74.91 14.20 89.11  4.19 0.74 4.93  5.25 0.71 5.97 
Total mortality cost in 2013 US dollar 2,343,749,010 
 
a $ represents the actual cost in 2013 US dollars, while % represents the share of cost in each cell from the total mortality cost, 
in terms of percentage. For instance, White- non Hispanic males between the ages of 18 and 24, had $247.09 million mortality 
cost, which accounts for 10.54% of the total mortality cost. 
M = Million; B = Billion. 
 
 
 
Table 4-23. The societal cost of anxiety disorders for the U.S. adult population in 2010. 
 
  Indirect cost   
Overall direct medical cost  Morbidity cost Mortality cost  Societal cost 
$33,709,900,849 (69.12%)  $12,718,495,520 (26.08%) $2,343,749,010 (4.81%)  $48,772,145,379 
 
Note: Costs are in 2013 US dollar values. 
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CHAPTER 5.    DISCUSSION 
 
 
Direct Medical Costs 
 
 
General Notes 
 
 Our results showed that almost 9% of the ambulatory adult population of the U.S. 
in 2009-2010 was diagnosed with anxiety disorder(s). This estimate is lower than the 
18.1% estimate for the 12-month prevalence of any anxiety disorder, reported by the 
National Comorbidity Survey Replication (NCS-R).9 This difference could be explained 
by the fact that in MEPS, medical conditions are self-reported; while in the NCS-R, a 
fully structured diagnostic interview was conducted to identify individuals with a 
particular mental disorder. So, it is possible that some individuals with mild or moderate 
anxiety disorder did not receive the diagnosis at the time of interview. Another possibility 
is that some persons did not report their anxiety, simply because of the social stigma 
attached to mental disorders. All these can lead to under-representation of anxiety 
disorders in MEPS. Consistent with the NCS-R’s findings, this study also found that 
prevalence of anxiety disorders is higher among women. 
 
 Unlike the previous researchers, who collected data from several different data 
sources, only one database was used in the current study to estimate direct medical costs. 
Using multiple data sources may lead to data inconsistency. To avoid this issue, we used 
MEPS as the only data source for all analyses related to direct medical costs, since it 
contains comprehensive information regarding the health care utilization and cost for 
participants in the survey. 
 
 MEPS has been widely used by previous researchers for the estimation of disease-
attributable expense.60-64,66,84-86 In fact, when it comes to highly prevalent diseases, MEPS 
is superior to administrative databases for cost estimation purposes in several ways. First 
of all, it contains detailed information on demographic and clinical characteristics of 
individuals, as well as their health care utilization and expenses. So, by controlling for all 
factors that may affect healthcare expenditures in analysis, researchers can estimate costs 
solely due to the condition of interest. Second of all, disease-attributable expenses can be 
presented as point estimates, as well as percentage of total costs of the disease population. 
This information, which cannot be gained using administrative data, provides a more 
sensible picture of the economic burden of a disease;65 Finally, MEPS is the only 
database which contains all required information to estimate direct medical expenditures 
attributable to a disease. So instead of getting data from several different data sources, 
which may lead to data inconsistency and later cast doubt on the reliability of results, 
only one database is used to collect data on healthcare utilization and costs. 
 
 The confidence in the current findings is also derived from the adaptation of a 
robust statistical analysis technique. In modeling healthcare cost data, an attempt was 
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made to reduce bias in estimates by selecting statistical techniques that considered the 
skewed nature of such data. 
 
 
Overall Direct Medical Cost 
 
 Using estimates from this study, the annual incremental direct medical 
expenditures attributable to anxiety disorders, for the U.S. ambulatory adult population, is 
at $33.71 billion in 2013 US dollars. This figure, representing more than 69% of the 
estimated societal cost, is obtained by multiplying the per-capita incremental cost of 
anxiety ($1657.52) by the national estimated prevalence of anxiety disorders in MEPS 
(20.34 million persons).  
 
 Previous estimates of direct medical costs of anxiety disorders, which were 
obtained in the late 90’s, range from $28.73 billion to $98.26 billion in 2013 US 
dollars.5,10 Even though our estimate falls within this range, it is not quite comparable 
with the previous findings. The type of methodology used to estimate the costs has a 
significant impact on results. DuPont et al.5 estimated the medical expenditures as the 
product of volume of services and unit prices or charges, and Greenberg et al.10 estimates 
were derived from a two-step multivariate regression approach, while we used the 
incremental cost approach. In addition, their study population was not limited to the U.S. 
ambulatory adult population, as ours was. Also, they did not include all diagnoses of 
anxiety disorders in their analysis and considered different cost categories in estimating 
cost of illness. For instance, DuPont et al.5 used charges instead of costs, did not include 
costs due to PTSD, and almost 70% of their cost estimate ($19.9 billion) was due to costs 
for institutionalized population, i.e. those who reside in nursing homes and specialty 
mental health organizations. Greenburg et al.10 estimated cost of anxiety for individuals 
aged 15 to 54. They found that more than half of the costs of these disorders ($53 billion) 
were attributable to non-psychiatric direct medical expenditures. Interpreting this result, 
Greenburg et al. explained that “estimation of this component was based on results from 
a single staff–model HMO that may not be fully generalizable to the entire 
population.”10(p. 431)  
 
 
Cost by Category of Healthcare Services 
 
 With respect to categories of direct medical cost, inpatient visits (35.00%), 
prescription medications (32.78%), and office-based medical provider visits (22.34%) 
together accounted for almost 93% of the overall incremental costs associated with 
anxiety disorders. Emergency room cost, representing almost 3% of overall medical 
costs, was also slightly higher for sufferers of anxiety. These findings are consistent with 
the known healthcare utilization pattern and treatment seeking behavior of individuals 
with anxiety disorders. Marciniak, Lage, Landbloom, Dunayevich, and Bowman15 
estimated the medical and productivity cost of anxiety disorders using data from a large 
employer database. Their results showed that employees with anxiety disorders had 
 74 
higher inpatient hospital costs as well as higher prescription medications, medical 
provider visits, and emergency care costs.  
 
 The high cost of office-based medical provider visits and prescription medications 
can also be explained through the treatment seeking behavior of individuals with anxiety 
disorders. Treatment options for anxiety disorders include pharmacotherapy, 
psychotherapy, or combination of both. With the recent advances in psychotherapy 
techniques and pharmacotherapy products, such as Cognitive-Behavioral Therapy (CBT) 
and Selective Serotonin Reuptake Inhibitors (SSRIs) proven to be very effective in 
treating anxiety disorders, treatment utilization for these conditions has significantly 
increased throughout the time.87,88 As such, office-based medical provider visits and 
prescription medications are expected to account for the majority of overall cost of illness 
associated with anxiety disorders. 
 
 . To effectively reduce the cost of anxiety disorders, more attention needs to be 
geared towards these three categories of care. For instance, further studies should 
investigate the underlying reasons for high hospitalizations in patients with anxiety 
disorders, and examine whether these hospitalizations are potentially preventable. 
 
 
Cost for Different Sub-populations 
 
 Knowing which sub-population incurs higher costs, policymakers and clinicians 
will be able to develop tailored disease management programs, by considering the 
specific characteristics of the target sub-populations. 
 
 Our results showed that the following sub-populations accounted for the majority 
of the overall direct medical costs associated with anxiety disorders in their category: 
Females ($2137.98), individuals 65 years and older ($2426.40), White non-Hispanics 
($1879.31), previously married individuals ($2305.23), those with high levels of 
education (i.e. master/PhD) ($2463.31), middle-income earners ($2048.08), those who 
reside in the Midwest ($2338.59), non-MSA residents ($2485.64), and dual eligible 
($6455.84). The only sub-populations, in which having anxiety disorder(s) was not 
associated with higher medical cost, were Hispanics, individuals with less than a high 
school diploma/GED, the uninsured, and those who were covered only by Medicaid, or 
other public insurances (such as Tricare).  
 
 Higher costs for females and White non-Hispanics can be explained through the 
higher prevalence of anxiety disorders among these sub-populations.30 With respect to 
insurance coverage, dual eligible followed by Medicare enrollees and private insurance 
holders had the highest portion of medical costs. These plans usually offer more generous 
benefits than Medicaid and other forms of public insurance. As such, it is expected for 
their members to have higher utilization and cost for services such as psychotherapy 
session, which are either not covered or limitedly covered by other plan types. The life-
time prevalence of anxiety disorders is the lowest for people 65 years and older; yet we 
found that this group of individuals accounted for the majority of cost. This can be 
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explained through the correlation between age and Medicare insurance coverage. Patients 
with middle income, as well as those with high educational level had high anxiety-related 
costs. This observation can be justified assuming that people with higher socioeconomic 
status are more aware of the importance of treatment seeking for their diseases. 
 
 As it was mentioned above, anxiety disorders were not associated with an 
increase in healthcare cost among Hispanics. Also, anxiety related costs for Black non-
Hispanics, even though statistically significant, were less than costs for White non-
Hispanics. One explanation for these observations could be the lower life-time prevalence 
of anxiety disorders among Hispanics and Black non-Hispanics, in comparison with 
White non-Hispanics.30 However, future research needs to be done to examine any 
potential barrier in receiving the treatment for anxiety disorders among minorities. 
 
 To our knowledge, there is no study in the literature examining cost of anxiety 
among different sub-populations. Murciniak et al.18 used MarketScan Databases to 
examine how medical conditions and demographic characteristics affect the costs of 
treating anxiety patients. The only demographic characteristics included in their analyses 
were gender, age, and insurance coverage. Similar to our findings, they concluded that 
females, older individuals, and those who have more comprehensive insurance coverage 
incurred higher costs.18 
 
 We broke down anxiety costs for Blacks and Whites, by sex, gender and 
geographic region. Our findings (i.e. considerable variation in incremental costs incurred 
by different sub-populations), demonstrate why it is important to calculate values for sub-
groups; and highlight the need for future studies to figure out the underlying causes of 
such variations. Of particular interest is the much larger costs for Black non-Hispanics in 
the Northeast ($3899.40) and for Black non-Hispanic males aged 45 and older 
($3932.22). These findings deserve additional study to determine the reasons for such 
higher costs in theses sub-populations. 
 
 
Indirect Costs 
 
 Based on the prevalence of self-reported anxiety disorders in MEPS and suicide 
data from NVSS, the total annual indirect cost attributable to anxiety disorders was 
estimated at $15.06 billion in 2013 US dollars ($12.72 for morbidity $2.34 for mortality 
cost). This figure represents almost 31% of the estimated societal cost of anxiety 
disorders. 
 
 Like direct medical cost, the estimated morbidity cost is also based on the 
prevalence of self-reported anxiety disorders in MEPS. So, there is a possibility of under-
estimation of morbidity cost in this study (due to potential under-reporting of anxiety 
disorders in MEPS).  
 
 There are only two studies that provided national estimates of indirect costs for 
anxiety disorders. Greenberg et al.10 estimations of morbidity and mortality costs are 
 76 
$7.44 billion and $2.12 billion (in 2013 US dollars) respectively. Even though their 
analysis technique for mortality cost is pretty similar to ours, their estimation of 
morbidity cost is not quite comparable with our results, because: 
 
?  They estimated productivity loss due to anxiety disorders only for the employed 
individuals, while we considered both employed and unemployed individuals in 
the analysis.  
 
? For employed individuals, they defined morbidity cost as the cost due to 
absenteeism, plus reduced productivity while at work. The latter represented more 
than 87% of their estimated morbidity cost. However, we did not include this 
component (reduced productivity while at work) in our analysis. 
 
? To get the number of missed work days due to anxiety disorders, we used 
regression analysis while they applied a 40% impairment rate to the total number 
of work cutbacks. 
 
 DuPont et al.,5 also provided estimates of morbidity and mortality cost at $59.83 
billion and $2.30 billion (in 2013 US dollars), respectively. In calculating the mortality 
cost, they adopted the same methodology as ours, but their estimation of morbidity cost 
was based on impairment rate, and thus is not comparable with our findings. 
 
 
Societal Cost 
 
 The societal cost of anxiety disorders were estimated at 48.72 billion in 2013 US 
dollars. Figure 5-1 shows the proportion of each cost component from the societal cost of 
anxiety disorders for the ambulatory adult population of the United States.  
 
 This study used nationally representative databases along with a robust statistical 
analysis technique to provide the most comprehensive and recent estimates of societal 
cost of anxiety disorders among adults in the U.S. The current study demonstrates 
conclusively that anxiety disorders, with the annual societal cost of $48.72 billion in 2013 
US dollars, absorb a significant portion of US healthcare resources and should be 
prioritized by policymakers and healthcare providers who aim to reduce downstream 
costs of mental disorders.  
 
 Almost 70% of societal cost of anxiety disorders was due to direct medical costs. 
We analyzed this category further by looking at the distribution of costs in different 
health delivery settings, and amongst different sub-populations. 
 
 Our findings may also influence policy under the new Affordable Care Act 
(ACA). The ACA, signed into law on March 2010, aims to: expand coverage for all 
Americans, enhance the quality of care, and lower healthcare costs.89 In this regard, 
economic evaluations, such as cost of illness studies, can serve as an important tool in 
creating a healthcare system with lower costs and higher quality of care. Cost of illness 
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Figure 5-1. Percentage of each cost component from the societal cost. 
 
 
studies are also useful in being able track healthcare costs over time to see if the increase 
access to healthcare and the cost-reductions in the ACA are having an effect. Cost of 
illness studies enable policymakers to identify medical conditions that absorb a 
significant portion of the US healthcare budget. These costly medical conditions may be 
investigated further to realize if resources are being distributed inefficiently, or if there is 
a need to invest in new, cost-effective treatment options. All these will lead to prioritizing 
scarce healthcare resources in a more efficient way, which eventually may lower the cost 
of care. However, the ACA lacks a mechanism to directly use economic evaluations, to 
reach these goals. As such, new healthcare policies are needed to support research that 
will help prioritize allocation of scarce healthcare resources. 
 
 
Limitations 
 
 This study has several limitations. Most importantly, our findings might have 
underestimated the direct medical expenditures, as well as indirect cost aspect of 
morbidity, attributable to anxiety disorders. As it was discussed earlier, individuals with 
anxiety disorders were identified as those who reported being diagnosed with this 
condition. So, prevalence of anxiety disorders might be under-reported in MEPS. As 
such, our findings should be interpreted with caution. Results from this study, due to 
potential under-representation of anxiety disorders in MEPS, should be interpreted as a 
conservative estimate of the societal cost of these conditions in the ambulatory adult 
population of the U.S. If we assume that health seeking behavior and healthcare 
utilization of individuals with anxiety disorders, who didn’t report their condition, is not 
systematically different from other individuals in the study population, then we can apply 
the estimated per-person incremental medical cost ($1657.52) to the NCS-R’s estimate of 
the 12-month prevalence of anxiety disorders (i.e. 18.1% of the adult population which is 
equal to 42.13 million persons); and it gives us the total direct medical cost of anxiety 
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disorders at $69.84 billion in 2013 US dollars. Similarly, assuming that productivity loss 
of sufferers who reported their anxiety is consistent with the rest of the population, the 
estimated morbidity cost would be $25.36 billion. 
 
 Second, some covariates such as history and severity of illness were not included 
in the analysis of direct medical cost, due to unavailability of this information in MEPS. 
Third, we studied the societal cost of anxiety disorders in the ambulatory adult population 
of the U.S. A more comprehensive study including all age groups, as well as patients in 
assisted living or nursing home facilities, in analysis would provide a more precise 
estimate of the economic burden of these conditions. Fourth, since only the first three 
digits of ICD-9 codes are shown in MEPS public use files, we couldn’t unbundle the 
umbrella category of anxiety disorders and report costs by each diagnosis of these 
conditions. Finally, in order to find the number of deaths due to anxiety disorders, we 
applied a 10% rate to the total number of suicides. Even though we have adopted this rate 
from previous relevant research, it may not be a very accurate estimate for anxiety-
induced suicides. Unfortunately, the national number of suicides for each specific 
diagnosis of mental illnesses is not still available. 
 
    
 79 
LIST OF REFERENCES 
 
 
1. National Health Expenditures 2011 Highlights. [Centers for Medicare & Medicaid 
Services]. 2012; http://www.cms.gov/Research-Statistics-Data-and-
Systems/Statistics-Trends-and-
Reports/NationalHealthExpendData/downloads/highlights.pdf. Accessed 
01/24/2013. 
 
2. OECD Health Data 2012 How Does the United States Compare. [Organisation for 
Economic Co-operation and Development]. 2012; 
http://www.oecd.org/unitedstates/BriefingNoteUSA2012.pdf. Accessed 
01/24/2013. 
 
3. Joel E, Segel BA. Cost-of-Illness Studies—A Primer. RTI-UNC Center of 
Excellence in Health Promotion Economics;2006. 
 
4. Rice DP. Cost of illness studies: what is good about them? Inj Prev. Sep 
2000;6(3):177-179. 
 
5. DuPont RL, Rice DP, Miller LS, Shiraki SS, Rowland CR, Harwood HJ. 
Economic costs of anxiety disorders. Anxiety. 1996;2(4):167-172. 
 
6. Anxiety Disorders- Common Characteristics. [AllPsych Online].  
http://allpsych.com/disorders/anxiety/index.html. Accessed 09/01/2012. 
 
7. Diagnostic and Statistical Manual of Mental Disorders (4th ed., text rev.). 
Washington, DC: American Psychiatric Association; 2000. 
 
8. Anxiety Disorders. Washington, DC: U.S. DEPARTMENT OF HEALTH AND 
HUMAN SERVICES; 2009. 
 
9. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, 
severity, and comorbidity of 12-month DSM-IV disorders in the National 
Comorbidity Survey Replication. Archives of general psychiatry. Jun 
2005;62(6):617-627. 
 
10. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety 
disorders in the 1990s. Journal of Clinical Psychiatry. Jul 1999;60(7):427-435. 
 
11. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity 
cost burden of the "top 10" physical and mental health conditions affecting six 
large U.S. employers in 1999. Journal of occupational and environmental 
medicine / American College of Occupational and Environmental Medicine. Jan 
2003;45(1):5-14. 
 80 
12. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the 
brain in Europe. European Journal of Neurology. Jun 2005;12 Suppl 1:1-27. 
 
13. Andlin-Sobocki P, Wittchen HU. Cost of anxiety disorders in Europe. European 
Journal of Neurology. Jun 2005;12 Suppl 1:39-44. 
 
14. Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A. Costs of 
nine common mental disorders: implications for curative and preventive 
psychiatry. The journal of mental health policy and economics. Dec 
2006;9(4):193-200. 
 
15. Marciniak M, Lage MJ, Landbloom RP, Dunayevich E, Bowman L. Medical and 
productivity costs of anxiety disorders: case control study. Depression and 
anxiety. 2004;19(2):112-120. 
 
16. Leon AC, Olfson M, Portera L. Service utilization and expenditures for the 
treatment of panic disorder. General hospital psychiatry. Mar 1997;19(2):82-88. 
 
17. Rees CS, Richards JC, Smith LM. Medical utilisation and costs in panic disorder: 
a comparison with social phobia. Journal of Anxiety Disorders. Sep-Oct 
1998;12(5):421-435. 
 
18. Marciniak MD, Lage MJ, Dunayevich E, et al. The cost of treating anxiety: the 
medical and demographic correlates that impact total medical costs. Depression 
and anxiety. 2005;21(4):178-184. 
 
19. Panzer PE, Regan TS, Chiao E, Sarnes MW. Implications of an SSRI generic step 
therapy pharmacy benefit design: an economic model in anxiety disorders. Am J 
Manag Care. Oct 2005;11(12 Suppl):S370-379. 
 
20. McLaughlin TP, Khandker RK, Kruzikas DT, Tummala R. Overlap of anxiety 
and depression in a managed care population: Prevalence and association with 
resource utilization. Journal of Clinical Psychiatry. Aug 2006;67(8):1187-1193. 
 
21. Stein MB, Cantrell CR, Sokol MC, Eaddy MT, Shah MB. Antidepressant 
adherence and medical resource use among managed care patients with anxiety 
disorders. Psychiatric services (Washington, D.C.). May 2006;57(5):673-680. 
 
22. Olfson M, Gameroff MJ. Generalized anxiety disorder, somatic pain and health 
care costs. General hospital psychiatry. Jul-Aug 2007;29(4):310-316. 
 
23. Roberge P, Marchand A, Reinharz D, et al. Healthcare utilization following 
cognitive-behavioral treatment for panic disorder with agoraphobia. Cogn Behav 
Ther. 2005;34(2):79-88. 
 81 
24. Siegel L, Jones WC, Wilson JO. Economic and life consequences experienced by 
a group of individuals with panic disorder. Journal of Anxiety Disorders. // 
1990;4(3):201-211. 
 
25. Souetre E, Lozet H, Cimarosti I, et al. Cost of anxiety disorders: impact of 
comorbidity. Journal of psychosomatic research. 1994;38 Suppl 1:151-160. 
 
26. Salvador-Carulla L, Segui J, Fernandez-Cano P, Canet J. Costs and offset effect in 
panic disorders. British Journal of Psychiatry - Supplement. Apr 1995(27):23-28. 
 
27. Patel A, Knapp M, Henderson J, Baldwin D. The economic consequences of 
social phobia. Journal of affective disorders. Apr 2002;68(2-3):221-233. 
 
28. Batelaan N, Smit F, de Graaf R, van Balkom A, Vollebergh W, Beekman A. 
Economic costs of full-blown and subthreshold panic disorder. Journal of  
Affective Disorders. Dec 2007;104(1-3):127-136. 
 
29. Acarturk C, Smit F, de Graaf R, van Straten A, Ten Have M, Cuijpers P. 
Economic costs of social phobia: a population-based study. Journal of affective 
disorders. Jun 2009;115(3):421-429. 
 
30. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime 
prevalence and age-of-onset distributions of DSM-IV disorders in the National 
Comorbidity Survey Replication. Arch Gen Psychiatry. Jun 2005;62(6):593-602. 
 
31. Kirschstein R. Disease-Specific Estimates of Direct and Indirect Costs of Illness 
and NIH Support: Fiscal Year 2000 Update. 2005; 
http://ospp.od.nih.gov/ecostudies/COIreportweb.htm. 
 
32. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current 
practices and procedures. Milbank Mem Fund Q Health Soc. Summer 
1982;60(3):429-462. 
 
33. MEPS HC-135I: Appendix to MEPS 2010 Event Files  HC-135A - HC-135H 
Rockville, MD: Agency for Healthcare Research and Quality-Center for 
Financing, Access, and Cost Trends; 2012. 
 
34. Rice DP. Estimating the cost of illness. Am J Public Health Nations Health. Mar 
1967;57(3):424-440. 
 
35. Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating 
indirect costs of disease. Soc Sci Med. May 1992;34(9):1005-1010. 
 
36. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost 
method for measuring indirect costs of disease. J Health Econ. Jun 
1995;14(2):171-189. 
 82 
37. Johannesson M, Karlsson G. The friction cost method: a comment. J Health Econ. 
Apr 1997;16(2):249-255; discussion 257-249. 
 
38. Encyclopedia of Public Health. Vol 1. 1 ed: Springer; 2008. 
 
39. Chapin CV. The value of human life. American journal of public health (New 
York, N.Y. : 1912). Feb 1913;3(2):101-105. 
 
40. Mushkin SJ, Collings FD. Economic costs of disease and injury. Public health 
reports (Washington, D.C. : 1974). Sep 1959;74:795-809. 
 
41. Fein R. Economics of Public Health. New York: Basic Books; 1958. 
 
42. Drummond M. Cost-of-illness studies: a major headache? PharmacoEconomics. 
Jul 1992;2(1):1-4. 
 
43. Edlund MJ, Swann AC. The economic and social costs of panic disorder. Hosp 
Community Psychiatry. Dec 1987;38(12):1277-1279, 1288. 
 
44. Konnopka A, Leichsenring F, Leibing E, Konig HH. Cost-of-illness studies and 
cost-effectiveness analyses in anxiety disorders: a systematic review. J Affect 
Disord. Apr 2009;114(1-3):14-31. 
 
45. Survey Background. 2009. 
http://meps.ahrq.gov/mepsweb/about_meps/survey_back.jsp. 
 
46. MEPS HC-138: 2010 Full Year Consolidated Data File. 2012; 
http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h138/h138doc.sht
ml#2581UnitedStates. Accessed 4/01/2013. 
 
47. Machlin SR, Zodet MW, Nixon JA. Estimates of medical expenditures from the 
Medical Expenditure Panel Survey: Gains in precision from combining 
consecutive years of data. Paper presented at: Joint Statistical Meetings - Section 
on Survey Research Methods2003; Alexandria, VA. 
 
48. MEPS HC-036BRR: 1996-2009 Replicates for Variance Estimation File. 
Rockville, MD: Agency for Healthcare Research and Quality-Center for 
Financing, Access, and Cost Trends;2011. 
 
49. MEPS HC-137: 2010 Medical Conditions. 2012; 
http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h137/h137doc.sht
ml. Accessed 4/01/2013. 
 
 
 
 83 
50. Shirneshan E, Bailey J, Relyea G, Franklin BE, Solomon DK, Brown LM. 
Incremental direct medical expenditures associated with anxiety disorders for the 
U.S. adult population: Evidence from the Medical Expenditure Panel Survey. 
Journal of Anxiety Disorders. 10// 2013;27(7):720-727. 
 
51. BLS Information. [Bureau of Labor Statistics].  
http://www.bls.gov/dolfaq/bls_ques26.htm. Accessed 10/01/2012. 
 
52. Affordable Care Act. 2013; 
http://www.medicaid.gov/affordablecareact/affordable-care-act.html. Accessed 
08/21/2013. 
 
53. Labor Force Statistics from the Current Population Survey. Bareau of Labor 
Statistics. http://bls.gov/data/. Accessed 11/05/2012. 
 
54. CPI Detailed Report Data for March 2013. Washington, DC U.S. Bureau of 
Labor Statistics, Division of Consumer Prices and Price Indexes; 05/10/2013 
2013. 
 
55. About NCHS. [Center for Disease Control and Prevention].  
http://www.cdc.gov/nchs/about/policy/quality.htm. Accessed 11/01/2012. 
 
56. Deaths, percent of total deaths, and death rates for the 15 leading causes of death 
in 5-year age groups, by Hispanic origin, race for non-Hispanic population and 
sex: United States, 2010. Mortality Tables 2012; 
http://www.cdc.gov/nchs/nvss/mortality_tables.htm. Accessed 11/25/2012. 
 
57. Deaths, percent of total deaths, and death rates for the 15 leading causes of death 
in 10-year age groups, by Hispanic origin, race for non-Hispanic population and 
sex: United States, 2010. Mortality Tables 2012; 
http://www.cdc.gov/nchs/nvss/mortality_tables.htm. Accessed 11/25/2012. 
 
58. Deaths, percent of total deaths and rank order for 113 selected causes of death and 
Enterocolitis due to Clostridium difficile, by Hispanic origin, race for non-
Hispanic origin and sex, United States, 2010. Mortality Tables 2012; 
http://www.cdc.gov/nchs/nvss/mortality_tables.htm. Accessed 11/25/2012. 
 
59. Murphy SL, Xu JQ, Kochanek KD. Deaths: Final Data for 2010. National Vital 
Statistics Reports. Hyattsville, MD: National Center for Health Statistics;2013. 
 
60. Balu S, Thomas J, 3rd. Incremental expenditure of treating hypertension in the 
United States. Am J Hypertens. Aug 2006;19(8):810-816; discussion 817. 
 
61. Bhattacharyya N. Incremental healthcare utilization and expenditures for allergic 
rhinitis in the United States. The Laryngoscope. 2011;121(9):1830-1833. 
 84 
62. Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the 
United States. Journal of Asthma. Feb 2009;46(1):73-80. 
 
63. Kawatkar AA, Jacobsen SJ, Levy GD, Medhekar SS, Venkatasubramaniam KV, 
Herrinton LJ. Direct medical expenditure associated with rheumatoid arthritis in a 
nationally representative sample from the Medical Expenditure Panel Survey. 
Arthritis care & research. Nov 2012;64(11):1649-1656. 
 
64. Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates and patterns of direct 
health care expenditures among individuals with back pain in the United States. 
Spine. Jan 1 2004;29(1):79-86. 
 
65. Olin G, Machlin SR, Rhoades J. Estimating the cost of illness: The case of 
diabetes. 2008. 
 
66. Raval AD, Sambamoorthi U. Incremental healthcare expenditures associated with 
thyroid disorders among individuals with diabetes. Journal of thyroid research. 
2012;2012. 
 
67. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the 
Charlson comorbidity index with administrative data bases. Journal of clinical 
epidemiology. Dec 1996;49(12):1429-1433. 
 
68. Buntin MB, Zaslavsky AM. Too much ado about two-part models and 
transformation?: Comparing methods of modeling Medicare expenditures. 
Journal of Health Economics. 5// 2004;23(3):525-542. 
 
69. Breusch TS, Pagan AR. A Simple Test for Heteroscedasticity and Random 
Coefficient Variation. Econometrica. 1979;47(5):1287-1294 
 
70. Park R. Estimation with Heteroscedastic Error Terms. Econometrica. 
1966;34(4):888. 
 
71. Industries at a Glance. [Bureau of Labor Statistics].  
http://www.bls.gov/iag/tgs/iag814.htm. Accessed 11/01/2012. 
 
72. Akazawa M, Sindelar JL, Paltiel AD. Economic costs of influenza-related work 
absenteeism. Value in Health. 2003;6(2):107-115. 
 
73. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug 
abuse and mental illness, 1985 and 1988. Public health reports (Washington, D.C. 
: 1974). May-Jun 1991;106(3):280-292. 
 
74. Employment Cost Index. Bureau of Labor Statistics. http://www.bls.gov/data/. 
Accessed 06/ 24/2013. 
 85 
75. Siegel JE, Torrance GW, Russell LB, Luce BR, Weinstein MC, Gold MR. 
Guidelines for pharmacoeconomic studies. Recommendations from the panel on 
cost effectiveness in health and medicine. Panel on cost effectiveness in health 
and medicine. PharmacoEconomics. Feb 1997;11(2):159-168. 
 
76. SAS Institute Inc. SAS/STAT® 9.3 User’s Guide. Cary. NC: SAS Institute Inc; 
2011. 
 
77. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp. 
LP; 2011. 
 
78. O’brien R. A Caution Regarding Rules of Thumb for Variance Inflation Factors. 
Qual Quant. 2007/10/01 2007;41(5):673-690. 
 
79. Schoen C, Osborn R, Squires D, Doty MM, Pierson R, Applebaum S. How health 
insurance design affects access to care and costs, by income, in eleven countries. 
Health affairs (Project Hope). Dec 2010;29(12):2323-2334. 
 
80. Buchmueller TC, Grumbach K, Kronick R, Kahn JG. Book Review: The Effect of 
Health Insurance on Medical Care Utilization and Implications for Insurance 
Expansion: A Review of the Literature. Medical Care Research and Review. 
February 1, 2005 2005;62(1):3-30. 
 
81. Hurd MD, McGarry K. Medical insurance and the use of health care services by 
the elderly. Journal of Health Economics. 4// 1997;16(2):129-154. 
 
82. Stanton MW, Rutherford MK. The high concentration of U.S. health care 
expenditures. Rockville, MD: Agency for Healthcare Research and Quality;2005. 
06-0060. 
 
83. Alemayehu B, Warner KE. The lifetime distribution of health care costs. Health 
services research. Jun 2004;39(3):627-642. 
 
84. Kim MH, Johnston SS, Chu BC, Dalal MR, Schulman KL. Estimation of total 
incremental health care costs in patients with atrial fibrillation in the United 
States. Circulation. Cardiovascular quality and outcomes. May 2011;4(3):313-
320. 
 
85. Yelin E, Trupin L, Cisternas M, Eisner M, Katz P, Blanc P. A national study of 
medical care expenditures for respiratory conditions. European Respiratory 
Journal. Mar 2002;19(3):414-421. 
 
86. Yoon D, Frick KD, Carr DA, Austin JK. Economic impact of epilepsy in the 
United States. Epilepsia. Oct 2009;50(10):2186-2191. 
 86 
87. Olfson M, Marcus SC, Wan GJ, Geissler EC. National trends in the outpatient 
treatment of anxiety disorders. Journal of Clinical Psychiatry. Sep 
2004;65(9):1166-1173. 
 
88. Treatment. Anxiety Disorder association of America 2013; 
http://www.adaa.org/finding-help/treatment. Accessed 06/11/2013. 
 
89. Affordable Care Act. http://www.medicaid.gov/affordablecareact/affordable-care-
act.html. Accessed 08/21/2013. 
 
  
 87 
VITA 
 
 
 Elaheh Shirneshan was born in Iran in 1981. She finished her bachelor’s and 
master’s degree in Industrial Engineering in 2005 and 2009, respectively. In fall 2010, 
she was accepted at the University of Tennessee Health Science Center as a graduate 
student in the Ph.D. program (Major: Health Outcomes and Policy Research).She 
graduated from this program in December 2013. 
 
 
